

Main program



Joint SSORL / SSAI Meeting 2016

Swiss Society of Oto-Rhino-Laryngology, Head and Neck Surgery
Swiss Society for Allergology and Immunology

"Where science and clinic meet"



Schweizerische Gesellschaft für Oto-Rhino-Laryngologie, Hals- und Gesichtschirurgie
Société suisse d'Oto-Rhino-Laryngologie et de Chirurgie cervico-faciale
Società Svizzera di Otorinolaringoiatria e di Chirurgia cervico-facciale
www.ortl-hno.ch



Swiss Society
for Allergology
and Immunology

Jointly organized with the
Jürg Tschopp Memorial Symposium
April, 27th, 2016

April 28th-29th, 2016

Music Convention Centre, Montreux, Switzerland
www.imk.ch/ssorl-ssai2016

Damit unvergessliche Momente unvergesslich bleiben:

auch bei
Tinnitus
und
Schwindel



- Verzögert die Progression der Demenz¹
- nur 1 x täglich 240 mg
- stark bei kognitiven Einbussen^{2,3,4}
- optimale Ergänzung zum Zeller ZNS-Portfolio
- Liste B, kassenzulässig

www.zellermedical.ch

rezirkane® 240 mg – Zusammensetzung: Eine Filmtablette enthält 240 mg quantifizierten, raffinierten Ginkgotrockenextrakt aus *Ginkgo biloba*-Blättern (entsprechend 52.8–64.8 mg Flavonoide (berechnet als Flavonoidglykoside), 6.24–7.68 mg Bilobalid, 6.72–8.16 mg Ginkgolide A, B und C und maximal 5 ppm Ginkgolsäure; Extraktionsmittel Aceton 60% (m/m), Droge-Extrakt-Verhältnis 35–67:1). **Indikation/Anwendungsmöglichkeiten:** Zur symptomatischen Behandlung von nachlassender geistiger Leistungsfähigkeit mit Gedächtnis- und Konzentrationsstörungen. Zur unterstützenden Behandlung bei ausgeschöpftem Gehirntuning bei peripherer arterieller Verschlusskrankheit (*Claudicatio intermittens* im Stadium II nach FONTAINE) unter Fortführung des Gehirntunings. Bei Vertigo unbekannter Ursache. Zur adjuvanten Therapie bei Tinnitus (Ohrrausche). **Dosierung/Anwendung:** Erwachsene ab 18 Jahren: Tagesdosis von 120–240 mg *Ginkgo biloba*-Extrakt, in 1–2 Einzeldosen. Die Filmtabletten werden unzerkaut mit ausreichend Flüssigkeit eingenommen. **Kontraindikationen:** Überempfindlichkeit gegen *Ginkgo biloba*-Extrakte oder einen der verwendeten Inhaltsstoffe (Hilfsstoffe) des Arzneimittels, bei Schwangerschaft. **Interaktionen:** Bei gleichzeitiger Gabe von *Ginkgo biloba*-Extrakten mit blutgerinnungshemmenden Arzneimitteln kann deren Wirkverstärkung nicht ausgeschlossen werden. Wie bei jedem Arzneimittel kann bei *Ginkgo biloba*-Extrakten nicht ausgeschlossen werden, dass es die Metabolisierung verschiedener anderer Arzneimittel über Cytochrome P450, 3A4, 1A2, 2E1 und 2C9 beeinflusst, was wiederum die Wirksamkeit und/oder die Wirkdauer verändern kann. So besteht bei der gleichzeitigen Einnahme von *Ginkgo biloba*-Extrakten mit Calciumantagonisten wie Nifedipin und Diltiazem, das Risiko für höhere Wirkspiegel während bei der gleichzeitigen Einnahme mit oralem Theophyllin das Risiko von niedrigeren Wirkspiegeln besteht. **Warnhinweise und Vorsichtsmassnahmen:** Bei einer bestehenden Blutungsneigung (Hämorrhagische Diathese) und/oder bei der gleichzeitigen Anwendung blutverdünnender Arzneimittel sollte die Einnahme von *Ginkgo biloba*-Extrakten nur nach Rücksprache mit einem Arzt erfolgen. Auf Grund von einzelnen Hinweisen, dass die Einnahme von *Ginkgo biloba*-Extrakten die Blutungsanfälligkeit erhöhen kann, sollte rezirkane® sicherheitshalber 36 Stunden vor operativen Eingriffen abgesetzt werden. Es ist nicht ausgeschlossen, dass bei Patienten mit Epilepsie *Ginkgo biloba*-Extrakt induzierte Anfälle ausgelöst werden könnten. **Unerwünschte Wirkungen:** Magen-Darm-Beschwerden (z.B. Übelkeit), Kopfschmerzen, (Dreh-)Schwindel, Herzklopfen, selten allergische Reaktionen (Hautrotung, Schwellung, Juckreiz). Bei überempfindlichen Personen kann es zum allergischen Schock kommen. **Packungsgrößen:** 30 und 60 Filmtabletten. **Verkaufskategorie:** B, kassenzulässig. **Zulassungsinhaber:** Zeller Medical AG, 8590 Romanshorn, Tel.: 071 466 05 00. **Ausführliche Angaben** entnehmen Sie www.swissmedicinfo.ch (Stand der Information: Februar 2014).¹ Rainer M. et al. (2013), *Ginkgo biloba* extract EGb 761® in the treatment of dementia: a pharmaco-economic analysis of the Austrian setting. *Wien Klin Wochenschr.* 2013 Jan; 125(1-2): 8-15. ²HMPC (2015) European Union herbal monograph on *Ginkgo biloba* L., folium (EMA/HMPC/321097/2012). ³HMPC (2014) Assessment report on *Ginkgo biloba* L., folium (EMA/HMPC/321095/2012). ⁴rezirkane® 120 mg/ rezirkane® 240 mg; www.swissmedicinfo.ch (Abrufdatum: 02.11.2015).

1115/831

Table of Contents

Welcome to Montreux	2
General Information	3-9
Travel Information	11
Program	
Thursday, April 28th, 2016	14-29
Friday, April 29th, 2016	30-39
Meetings	41
Posters SSAI	43-49
Posters SSORL	51-53
Invited Speakers & Chairs Joint SSORL/SSAI Meeting 2016	55-61
Industrial exhibition	62
Exhibition plan	63

Welcome to Montreux

Dear colleagues,

We would like to cordially welcome you to the joint meeting of the Swiss Society of Oto-rhino-laryngology, Head and Neck Surgery and the Swiss Society for Allergology and Immunology.

For our congress, we have chosen the wonderful Swiss Riviera at the border of the Lac Lemman which offers a unique environment, where work can be ideally combined with spending relaxing hours together with your colleagues and meeting new people.

The main components of «Montreux 2016» are the Annual Meeting of the Swiss Society for Allergology and Immunology and the Springtime Meeting of the Swiss Society of Oto-rhino-laryngology, Head and Neck Surgery held concomitantly on Thursday & Friday, 28th & 29th of April. The scientific contributions of young researchers in all fields of our specialties and the basic science sessions of allergologists and immunologists will be enriched by three joint interdisciplinary plenary sessions. The congress is preceded by the extraordinary «Jürg Tschopp Memorial Symposium» on Wednesday, 27th of April.

The exciting program of «Montreux 2016» is built on numerous ideas, followed by the hard work of dedicated colleagues, demonstrating their great enthusiasm and productivity. As a result, you will find a large spectrum of clinical, translational, and basic scientific sessions. The joint SSAI / SSORL meeting provides a rich program under the slogan «Where Science and Clinic Meet» and offers the unique opportunity to share experience and knowledge among the respective experts in the field. The «Memorial» is a great opportunity to hear about the most recent scientific advances in biology, with specific emphasis on inflammatory mechanisms.

Many promising developments in medicine, biological sciences and technologies have been brought about in recent years. The enhancement of support from the public, government, private and philanthropic sectors opens new doors and bears great potential for new opportunities. These opportunities are best realized when people meet together, make initiatives for new projects and developments, and consider meaningful policy changes.

The aims of «Montreux 2016» are to deepen our knowledge, to develop collaborations, extend our professional network, and to promote favorable developments in our specialties that span a rich and diverse biomedical environment.

Above all, we hope that you will enjoy your time in Montreux, and that you can share your knowledge and enthusiasm with colleagues and friends. We wish you a successful and satisfactory stay, and thank you for your attendance and contributions.

Yours sincerely,

The members of the SSAI & SSORL steering and scientific committees.

General Information

Date	April 28th - 29th, 2016
Congress venue	Music & Convention Centre Avenue Claude Nobs 5, 1820 Montreux, Switzerland www.2m2c.ch
Congress website	www.imk.ch/ssorl-ssai2016 www.orl-hno.ch
Website of the societies	• Swiss Society of Otorhinolaryngology, Head and Neck Surgery www.orl-hno.ch • Swiss Society for Allergology and Immunology www.sgai-ssai.ch
Joint steering committee	Vincent Aubert, MD Prof. Nicolas Fasel, PhD Prof. Greta Guarda, PhD Prof. Philippe Pasche, MD Prof. Daniel Speiser, MD Prof. François Spertini, MD Prof. Sandro Stöckli, MD Prof. Antje Welge-Lüssen, MD
Joint scientific committee	Vincent Aubert, MD Prof. Nicolas Fasel, PhD Prof. Greta Guarda, PhD Dominik Harder, MD Basile Landis, MD Thomas Schweri, MD Prof. Christian Simon, MD Michael Soyka, MD Prof. Daniel Speiser, MD Prof. François Spertini, MD Prof. Antje Welge-Lüssen, MD
Organisational Committee Young Researcher Events	Slavica Masina, PhD Natalie Neubert, PhD student Riccardo Turrini, PhD

General Information

Scientific committee SSAI Montreux 2016	Hans Acha-Orbea	Olivier Michielin
	Vincent Aubert	Carolina Obregon-Espinel
	Blaise Corthesy	Guiseppe Pantaleo
	George Coukos	Matthieu Perreau
	Curdin Conrad	Camillo Ribi
	Alena Donda	Thierry Roger
	Nicolas Fasel	Pedro Romero
	Michel Gilliet	Alexander So
	Greta Guarda	Daniel Speiser
	Alexandre Harari	François Spertini
	Werner Held	Fabienne Tacchini
	Sanjiv Luther	Margot Thome
	Jean-Pierre Mach	Dominique Velin
	Benjamin Marsland	Anne Wilson
	Fabio Martinon	Dietmar Zehn

Administrative secretariat **IMK** Institute for medicine and communication Ltd
Münsterberg 1, CH-4001 Basel
Phone +41 61 271 35 51 | Fax +41 61 271 33 38
congress@imk.ch | www.imk.ch

Opening hours congress secretariat Thursday, April 28th, 2016: 08:15-18:30 h
Friday, April 29th, 2016: 07:30-17:00 h

Opening hours industrial exhibition Thursday, April 28th, 2016: 08:15-18:30 h
Friday, April 29th, 2016: 07:30-17:00 h

Registration Please register online:
SSAI and guests: www.imk.ch/ssorl-ssai2016
SSORL: www.orl-hno.ch/d/veranstaltung

Registration fees (CHF)	SSORL/SSAI Meeting 1 Day	SSORL/SSAI Meeting 2 Days	Jürg Tschopp Memorial	Combi ticket
Member SSORL	0*	0*	150*	150*
Members SSAI	250	350	250	450
Non members	350	500	325	600
Students				
Assistant doctors	200	250	175	300
Nursing staff				

* Late registration fee from April 18th, 2016: + CHF 100.-

Cancellation fee **IMK** must be informed about the cancellations in written form until April 7th, 2016. We will be able to reimburse 50% of the congress fees. After April 7th, 2016 no refunds will be made.

General Information

Participation confirmation The participation confirmation will be distributed at the administrative secretariat during the congress.

Credits	April 28th, 2016	April 29th, 2016	Total
Swiss Society of Oto-Rhino-Laryngology, Head and Neck Surgery	8	8	16
Swiss Society for Allergology and Immunology	7	7	14
Swiss Society of Medical Oncology	8	8	16
Swiss Society of Pneumology			3
Swiss Society of Dermatology and Venereology	9	6.5	15.5
Swiss Society of General Internal Medicine			9
Swiss association of cantonal veterinarians (VSKT) Swiss Federal veterinary Office			1 day of continuous education in animal experimentation

Accommodation Rooms are available on request via www.imk.ch/ssorl-ssai2016

Grand Hôtel Suisse Majestic

Avenue des Alpes 45, 1820 Montreux, CH.

It is located in front of the railway station in the heart of Montreux.

Hotel Villa Toscane

Rue Du Lac 2-8, 1820 Montreux

It is located next to the congress centre in the heart of Montreux.

Social dinner Thursday, 28.04.2016 The social dinner takes place on Thursday, April 28th, 2016, from 19:30 h. We recommend to register early since the number of participants is limited. The costs for the dinner are at the expense of the participants. Dinner tickets for the social evening can be purchased while registering for the congress: CHF 120.- per person.

SSAI Young Researchers Party
Wednesday, 27.04.2016



Join the «Young Researchers Party» on Wednesday evening, April 27th, 2016 in the Caveau des Vignerons in Montreux.

It is a perfect opportunity for networking with other PhD students, PostDocs and young physicians. Food, drinks and entertainment are offered by the SSAI. Please register online until April 17th, 2016.

Dinners by invitation
Wednesday, 27.04.2016

- SSAI Presidential Dinner, Hotel Victoria in Glion
- SSORL Presidents Dinner, Auberge de l'onde in St-Saphorin
- Jürg Tschopp Memorial Dinner, Hotel Suisse Majestic in Montreux

General Information

Partner companies We thank the following partner companies for their generous support:

Premium partners



Partners



Supporters



General Information

Congress language	Plenary Sessions, Workshops, Seminars: presentations and slides in English. Posters and abstract presentations SSORL: in English, German or French Posters and abstract presentations SSAI: in English
Information for speakers and presenting authors	The lecture halls are equipped with a beamer and a computer. We ask the speakers to save their presentation on a USB memory drive and deliver it to the organizers at the AV-Check in «Salle Stravinski I» at latest one hour before the session.
Speed abstract presentations SSAI	The talk time for each speed presentation is 3 minutes (3 slides) followed by 1 minute of discussion. Please refer to the scientific program for the detailed schedule of the session.
Oral Presentations SSAI	The talk time for each free communication is 10 minutes followed by 2 minutes of discussion. Please refer to the scientific program for the detailed schedule of the session.
Oral Abstract Presentations SSORL	The talk time for each free communication is 7 minutes followed by 2 minutes of discussion. Please refer to the scientific program for the detailed schedule of the session.
Poster exhibition	All posters are exposed during the entire 2 days of the meeting. Posters have to be in the format AO portrait 118.9cm x 84.1cm (height x width). Hang-up of the posters in Foyer Miles Davis: Thursday, April 28th, 2016, 08:15–11:00 h.
Posterwalk SSAI	Thursday, April 28th, 2016, 12:30 –13:15 h • Basic Immunology - Group I: P01-P18 • Clinical, laboratory and translational immunology - Group I: P35-P53 Friday, April 29th, 2016, 11:30 –12:15 h • Basic Immunology - Group II: P19-P34 • Clinical, laboratory and translational immunology - Group II: P54-P69 • Allergology / Case reports in allergology: P70-P75
Posterviewing SSORL	Thursday, April 28th, 2016, 15:30 –16:30 h During the posterwalk/posterviewing, the presenters are asked to briefly summarize their findings.

broad product spectrum of allergy and immunotherapies available!

If only
everything
was so well
documented...

The logo for SQ quality, featuring a large red 'SQ' with the word 'quality' in blue above the 'Q' and a registered trademark symbol.

REPRODUCIBILITY

General Information

- Abstract book** A PDF with the submitted abstracts and the speakers' abstracts will be made available for download at the following websites one day before the meeting:
SSORL: www.orl-hno.ch | **SSAI:** www.imk.ch/ssorl-ssai2016
- Awards SSORL** **Best of Papers SSORL**
 The best talks and posters made by assistant doctors-in-training will be awarded by the task group «Awards and Tributes». Candidates for «Best of Papers SSORL» are marked with «#» in the corresponding session.
- Grand Prix SSORL 2016**
 Every two years the SSORL awards a prize to doctors for outstanding scientific work in the field of otorhinolaryngology, its subfields and adjacent disciplines. The prize is endowed with CHF 5'000.-.
- Awards SSAI** **Poster prizes sponsored by Biotest (Schweiz) AG**
 Three poster prizes, each at the amount of CHF 1'000.- will be awarded to the first author of the best poster «Basic Immunology», «Allergology» and «Clinical Immunology/Diagnostic Laboratory Immunology».
- Brunello Wüthrich Allergy Poster Prize** (CHF 1'000.-) will be awarded to an original and interesting allergy case description.
- Joint award session** The Joint award session will take place April, 29th, 2016 from 16:30-17:00 h.

((TINNITUS)) *und* SCHWINDEL



Symfona® forte
Stark auch bei Schwindel
und Tinnitus

SYMFONA® 

Symfona®/Symfona® forte/Symfona® 240 mg. Z: Ginkgo biloba-Extrakt, 60 mg/120 mg/240 mg. **G:** S., S. forte : Kapsel, S. 240 mg: Film-tablette. **I:** S., S. forte, S. 240 mg: symptomatische Behandlung von Einbussen in der mentalen Leistungsfähigkeit. S., S. forte: Vertigo, Tinnitus, Adjuvans bei Claudicatio intermittens. **D:** S.: 2x 1-2 Kaps./Tag, S. forte: 2x 1 Kaps./Tag, S. 240 mg: 1 Tab./Tag. **KI:** Überempfindlichkeit gegen Ginkgo biloba-Zubereitungen, Kinder <12 Jahre. **VM:** Einnahme vor operativen Eingriffen mit Arzt besprechen. **S/S:** Kein Risiko für das Kind bekannt, aber keine wissenschaftlichen Untersuchungen verfügbar. **UW:** Sehr selten leichte Magen-Darm-Beschwerden, Kopfschmerzen, allergische Hautreaktionen. Einzelfälle von Blutungen (ursächlicher Zusammenhang mit Ginkgo-Zubereitungen nicht gesichert). **IA:** Wechselwirkung mit Arzneimitteln, die die Blutgerinnung hemmen, nicht ausgeschlossen. Im Falle einer gleichzeitigen oralen Einnahme von Theophyllin, Risiko einer Abnahme der biologisch wirksamen Konzentration dieses Mittels. **P:** S.: 50 und 100, S. forte: 60 und 120, S. 240 mg: 30 und 60. **Liste B,** kassenzulässig. Detaillierte Informationen: www.swissmedinfo.ch. Stand der Information: März 2015. Vifor SA, CH-1752 Villars-sur-Glâne.

Travel Information

Music & Convention Centre | www.2m2c.ch
Avenue Claude Nobs 5, 1820 Montreux, Switzerland



Arrival by plane

Geneva airport conveniently has its own train station. It is a destination for all the major international airlines and makes the Montreux Riviera region easy to reach from around the world (Geneva airport – Montreux: 1 hour by car or 1 hour 8 minutes by train).

Montreux by car

The Montreux Riviera region is accessible by the A1 motorway connecting Zurich, Bern, Lausanne and Geneva. Exit the A1 near Lausanne and take the A9 motorway to Montreux.

Leaving Basel, the A2 motorway allows access to the Montreux Riviera region thanks to its link with the A12, which converges from Fribourg to Vevey. This motorway is worth the drive with its pastoral landscapes and the fabulous view of Lake Geneva as it descends towards Vevey/Montreux.

Geneva – Montreux: 1 hour | Zurich – Montreux: 2 hours

Montreux by train

Excellent railroad connections to Montreux are offered from Geneva (1 hour) and Zurich (2.5 hours, change in Lausanne). Travelling from Lausanne, the journey will last 20 minutes.

Geneva – Montreux: 1 hour | Zurich – Montreux: 2 1/2 hours | Lausanne – Montreux: 20 minutes

You can consult the train schedule via www.sbb.ch

Jürg Tschopp Memorial

Symposium



Organized with the
Joint SSORL / SSAI Meeting 2016
April 28th-29th, 2016

April 27th, 2016

Music & Convention Centre, Montreux, Switzerland

www.imk.ch/ssorl-ssai2016

Jürg Tschopp Memorial Symposium

Program | Wednesday, April 27th, 2016 | Miles Davis Hall

10:30–10:45	Welcome Nicolas Fasel, University of Lausanne, Switzerland
10:45–11:30	Molecular mechanisms of lymphocyte activation and lymphoma development Chair: Nicolas Fasel, University of Lausanne, Switzerland Margot Thome, University of Lausanne, Switzerland
11:30–12:15	Functional diversity in macrophage/monocyte subsets Chair: Margot Thome, University of Lausanne, Switzerland Shizuo Akira, Osaka University, Japan
12:15–13:15	<i>Lunch</i>
13:15–14:00	The Non – Canonical inflammasome pathway Chair: Fabio Martinon, University of Lausanne, Switzerland Vishva Dixit, Genentech Inc., San Francisco, USA
14:00–14:45	Inflammasomes, dysbiosis and chronic disease Chair: Greta Guarda, University of Lausanne, Switzerland Richard Flavell, Yale University, New Haven, USA
14:45–15:15	<i>Coffee break</i>
15:15–16:00	p62/SQSTM1 – an autophagy receptor that links oxidative stress, inflammation and cancer Chair: Sanjiv Luther, University of Lausanne, Switzerland Michael Karin, University of California, San Francisco, USA
16:00–16:45	Turning discoveries on cell death into improved therapies for cancer Chair: Pascal Schneider, University of Lausanne, Switzerland Andreas Strasser, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
16:45–17:00	Closing remarks Nicolas Fasel, University of Lausanne, Switzerland
18:30–23:00	Memorial Dinner at the Hotel Suisse Majestic in Montreux (by invitation)

Schedule | Thursday, April 28th, 2016

Thursday

	Miles Davis Hall	Salle Stravinski VI-VIII	Salle Stravinski IV-V	Salle Stravinski II-III
09:15 - 09:45	Oral presentations I SSORL 16	Speed abstract presentations SSAI 17	Nasal endoscopy / non invasive fibroscopy WS01 16	Examination of nasal function WS04 16
09:45 - 10:15				
10:15 - 10:45	Coffee break in the industrial exhibition			
10:45 - 11:00	Welcome/Opening 18			
11:00 - 11:30	Joint plenary session I Immunodeficiencies 18			
11:30 - 12:00				
12:00 - 12:30				
12:30 - 13:00	Lunch in the industrial exhibition			
13:00 - 13:30				
13:30 - 14:00	Oral presentations II SSORL 18	Oral presentations SSAI Allergology 21	Oral presentations SSAI Translational Immunology 19	
14:00 - 14:30				
14:30 - 15:00	Satellite Symposium MEDA Pharma GmbH 23	Satellite Symposium Novartis Pharma Schweiz AG 23	Clinical Symposium SSAI Progress in vaccinology 23	
15:00 - 15:30				
15:30 - 16:00	Coffee break in the industrial exhibition			
16:00 - 16:30				
16:30 - 17:00	Oral presentations III SSORL 27		Clinical Symposium SSAI Asthma and rhinitis 25	
17:00 - 17:30				
17:30 - 18:00	Informationen aus dem Vorstand SSORL 27	General assembly SSAI 29	Future investigators meeting SSAI 29	
18:00 - 18:30				
18:30 - 19:00				
19:00 - 19:30				
from 19:30	Social Dinner			

- Joint SSORL/SSAI
- Satellite Symposium
- Break
- SSORL
- SSAI
- SSA

Salle Miles Davis V	Salle Miles Davis IV	Salle Miles Davis III	Foyer Miles Davis	
	Sialometry WS03 16	Skin tests WS02 16		09:15 - 09:45
				09:45 - 10:15
Coffee break in the industrial exhibition				10:15 - 10:45
				10:45 - 11:00
			Poster exhibition	11:00 - 11:30
				11:30 - 12:00
				12:00 - 12:30
Lunch in the industrial exhibition			Posterwalk SSAI 18	12:30 - 13:00
				13:00 - 13:30
Oral presentations SSAI Basic immunology I: Inflammation, innate immunity 19	Symposium Aerobiology and allergies 21		Poster exhibition	13:30 - 14:00
				14:00 - 14:30
Research Symposium SSAI Leukemia & Lymphoma 25				14:30 - 15:00
	General assembly SSA (Aerobiology) 25			15:00 - 15:30
Coffee break			Coffee break	Posterviewing SSORL 25
Research Symposium SSAI Phagocytes in health and disease 27				
			Poster exhibition	16:30 - 17:00
				17:00 - 17:30
		17:30 - 18:00		
		18:00 - 18:30		
				18:30 - 19:00
				19:00 - 19:30
Social Dinner				from 19:30



Meeting



Simultaneous translation DE/FR

Industrial exhibition: Foyer Accueil Stravinski **AV-Check:** Salle Stravinski I

Meetings: please refer to separate meeting list on page 41

09:15–10:15

Miles Davis Hall

Oral presentations I SSORL

Chairs: Antje Welge-Lüssen, Basel; Dominik Harder, Chur

09:15–09:25

Erholung intranasaler trigeminaler Sensitivität nach endoskopischer Nasennebenhöhlenoperation bei Polyposis nasi

Meusel T, Hackl Y, Hummel T, Iro H, Hornung J; Zürich, Erlangen (DE), Dresden (DE)

09:25–09:35

Extraluminal biodegradable splints to treat upper airway malacia; a pre-clinical proof of principle.

*Gorostidi F, Courbon C, Monnier Ph, Sandu K; Fribourg

09:35–09:45

Functional and anatomic study of the Eustachian tube by Tubomanometry together with Videoendoscopy in normal adults.

*Colin V, Asanau A, Timochenko A; St-Etienne, FR

09:45–09:55

Intranasal trigeminal sensitivity in seasonal allergic rhinitis: preliminary results

*Hool SL, Negoias S, Borner U, Friedrich H, Gschwend A, Meyer N, Sokolowska M, Akdis C, Helbling A, Caversaccio MD; Bern

09:55–10:05

Nasaler Septumperforations-Verschluss über einen geschlossenen Zugang

*Epprecht L, Soyka MB, Schlegel C, Kaufmann T; Zürich, Luzern

10:05–10:15

Trigeminal endonasale Perzeption, ein Prädiktor für das Outcome einer Septumplastik

Poletti-Muringaseril SC, Soyka MB; Zürich

09:15–10:15

Salle Stravinski IV–V

WS
01

Nasal endoscopy / non invasive fibroscopy

Michael Soyka, Zürich

09:15–10:15

Salle Miles Davis III

WS
02

Skin tests

Annette Leimgruber, Pully

09:15–10:15

Salle Miles Davis IV

WS
03

Sialometry

Alice Horisberger & Camillo Ribi, Lausanne

09:15–10:15

Salle Stravinski II–III

WS
04

Examination of nasal function (olfaction, trigeminal and others)

Basile Landis, Genève & Antje Welge-Lüssen, Basel

09:15–10:15

Salle Stravinski VI–VIII

Speed abstract presentations SSAI

Chairs: Natalie Neubert, Lausanne; Riccardo Turrini, Lausanne;
Christoph Müller, Bern, SSAI Honorary Member 2016

09:15–09:20

P43 | The role of S1PR1 agonism in thymus-dependent T-cell regeneration during acute graft-vs.-host disease

M Vollmer, S Dertschnig, W Krenger; Basel, London (UK)

09:20–09:25

P09 | Autologous IL-10–DC promote regulatory CD4+ T cells and prolong rat-to-mouse islets xenograft survival

N Madelon, E Montanari, Y Muller, J Pimenta, L Gruaz, L Buhler, G Puga Yung, JD Seebach; Genève

09:25–09:30

P56 | The IL-33/ST2 pathway contributes to intestinal tumorigenesis in humans and mice

KD Mertz, L Mager, MH Wasmer, T Junt, P Krebs; Liestal, Bern, Basel

09:30–09:35

P46 | The Spleen – A Novel Niche for Chronic Myeloid Leukemia Stem Cells

MA Amrein, ED Bühler, C Riether, AF Ochsenbein; Bern

09:35–09:40

P10 | T cell priming ability by activated, Nlr5-deficient DCs is unaffected despite partially reduced MHCI levels

G Rota, K Ludigs, S Siegert, A Tardivel, L Morgado, W Reith, A De Gassart, G Guarda; Lausanne, Genève

09:40–09:45

P48 | Adenovector minigene constructs and CD8+ T cell Memory Inflation

JM Colston, B Bolinger, B Ludewig, P Klennerman; Oxford (UK), St.Gallen

09:45–09:50

P01 | High prevalence of isotype-switched antibody response against carbohydrate structures

C Schneider, M Wehrli, DF Smith, RD Cumming, A Straumann, M Lötscher, A Zürcher, S von Gunten; Bern, Atlanta (US), Olten

09:50–09:55

P67 | A reversible mouse model of colitis allows to study the microbial, metabolic and immunological changes associated with remitting-relapsing inflammatory disorders in the intestine

M Faderl, N Corazza, M Noti, J Brasseit, E Steiner-Althaus, CKC Kwong Chung, S Rihs, I Brodard, M Beutler, R Mars, V Perreten, M Geuking, K McCoy, A Macpherson, B Stecher, U Sauer, Ch Mueller; Bern, Munich (DE), Zürich

09:55–10:00

P12 | CD4 T cells are required for both development and maintenance of intestinal inflammation in a new mouse model of reversible colitis

J Brasseit, E Steiner, M Faderl, W Kwong, N Corazza, M Noti, C Mueller; Bern

10:00–10:05

P55 | IL-22-induced antimicrobial peptides are key determinants of mucosal vaccine-induced protection against H pylori in mice

D Velin, M Moyat, H Bouzourene, W Ouyang, J Iovanna, JC Renaud; Lausanne, San Francisco (US), Marseille (FR), Brussels (BE)

10:05–10:10

P71 | Anaphylaxis to gadolinium-based contrast media and cross-reactivity to other substances – 3 cases

K Scherer, C Morales Mateluna, AJ Bircher; Basel

10:10–10:15

P72 | Cow's milk proteins in phytosanitary products: a new public health threat ?

J Wassenberg, I Rochat, MA Panchard; Vevey, Lausanne

10:15–10:45

Coffee break in the industrial exhibition

10:45-11:00
Miles Davis Hall

Welcome/Opening

11:00-12:30
Miles Davis Hall

Joint plenary session I – Immunodeficiencies

Chairs: Michael Soyka, Zürich; Janine Reichenbach, Zürich

11:00-11:30

Chronic Rhinosinusitis and immunodeficiency

Philippe Gevaert, Gent, BE

11:30-12:00

Leukemia, lymphoma and lymphoproliferative disorders

Sylvain Latour, Paris, FR

12:00-12:30

CVID – next generation

Klaus Warnatz, Freiburg, DE

12:30-13:30

Lunch in the industrial exhibition

12:30-13:30
Foyer Miles Davis

Posterwalk SSAI

Basic Immunology Group I: P01-P18

Chairs: Santiago Gonzalez, Bellinzona; Jörg Seebach, Genève

Clinical, laboratory and translational immunology Group I: P35-P53

Chairs: Pedro Romero, Lausanne; Pascale Roux-Lombard, Genève

13:30-14:30
Miles Davis Hall

Oral presentations II SSORL

Chairs: Basile Landis, Genève; Dorothe Veraguth, Zürich

13:30-13:40

Cricothyroid joint anatomy as a predicting factor for success of crico-thyroid approximation in trans-women

*Schwarzkopf M, Honegger F, Storck C; Basel

13:40-13:50

Look at Voice ! Laryngeal Muscle activity during Singing: A 3D Analysis on Professional Singers

*Unteregger F, Potthast S, Zwicky S, Schiwowa J, Storck C; Basel, Urdorf, Schlieren, Zürich

13:50-14:00

Smells like hell but not when thirsty: a connectivity fMRI study

*Friedrich H, Meier L, Federspiel A, Jann K, Morishima Y, Wiest R, Strik W, Landis BN, Caversaccio MD, Dierks T; Bern, Genf, Los Angeles (US)

14:00-14:10

Stonebreaker – Pneumatischer intrakorporaler Lithotripter – ein neues Kapitel in der Therapie der Sialolithiasis

Jakscha J; Basel

14:10-14:20

Thyroidectomy as a first line treatment for hyperthyroidism is associated with improved clinical recovery

Vital D, Morand GB, Meerwein C, Laske RD, Schmid C, Huber GF; Zürich

14:20-14:30

Trans-thyro-hyoid access to the larynx for endoscopic resection of early stage glottic cancer

Monnier Y, Schoettker P, Benoit Morisod B, Ikonomidis C, Simon C; Lausanne

13:30–14:30
Salle Miles Davis V

Oral presentations SSAI: Basic Immunology I

Inflammation, innate immunity

Chairs: Carsten Krieg, Zürich; Marcus Thelen, Bellinzona

13:30–13:42

Commensal bacteria control plasmacytoid dendritic cell recruitment and activation in injured skin

J Di Domizio, C Belkhdja, P Chenuet, T Murray, A Van Lierop, O Demaria, C Conrad, B Homey, DE Speiser, B Ryffel, M Gilliet; Lausanne, Orleans (FR), Düsseldorf (DE)

13:42–13:54

Microbiota-mediated fine-tuning of the threshold of intestinal inflammasome activation in host-microbial mutualism.

F Ronchi, AJ Macpherson, KD McCoy; Bern

13:54–14:06

Angiogenic factor-driven inflammation (ADIn) promotes extravasation of patrolling human, pro-angiogenic monocytes

A Sidibé, P Ropraz, S Jemelin, Y Emre, PF Bradfield, BA Imhof; Genève

14:06–14:18

Interleukin-7 Expression Marks a Distinct Population of Breast Tumor-Promoting Fibroblasts

M Boesch, M Novkovic, HW Cheng, L Onder, E Scandella, R Rodriguez, T Ruhstaller, B Thürlimann, B Ludewig; St.Gallen

14:18–14:30

Coagulation induced by C3aR-dependent NETosis drives protumorigenic neutrophils during small intestinal tumorigenesis.

S Guglietta, E Zagato, C Krieg, S Gandini, L Bao, G Penna, M Rescigno; Milan (IT), Zürich, Boston (US)

13:30–14:30
Salle Stravinski II-V

Oral presentations SSAI: Translational Immunology

Chairs: Lukas Flatz, St.Gallen; Gennaro De Libero, Basel

13:30–13:42

T lymphocytes contribute to differentiation of leukemic stem cells and promote leukemia development

CA Ruckstuhl, C Riether, AF Ochsenbein; Bern

13:42–13:54

IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms

L Mager, Y Banz, MH Wasmer, R Stuber, AP Theodorides, P Krebs; Bern, Zürich

13:54–14:06

Novel combination of in vivo expanded Tregs and CD154-CD40 co-stimulation blockade promotes allograft tolerance in naïve and sensitized mice

L Govender, M Pascual, D Golshayan; Lausanne

14:06–14:18

Innate Lymphoid Cells (ILCs): Novel players in human anti-tumor immunity?

B Salomé, S Trabanelli, D Mavilio, K Michaud, P Mangin, M Chevalier, S Abed Maillard, L Cagnon, J-P Rivals, DE Speiser, L Derré, P Mathevet, L Kandalaft, G Coukos, P Romero, C Jandus; Lausanne

14:18–14:30

PGD2-induced immunosuppressive ILC2-MDSC axis is enhanced in acute promyelocytic leukemia (APL)

S Trabanelli, M Chevalier, A Martinez Usatorre, M Lecciso, C Granclement, E Oppliger Leibundgut, GM Baerlocher, O Spinelli, A Rambaldi, D Vanhecke, H de Thé, D Mavilio, A Curti, G Coukos, P Romero, L Derré, C Jandus; Lausanne, Bologna (IT), Bern, Bergamo (IT), Paris (FR), Milan (IT)

**MEDA is pleased to invite you
to our company sponsored symposium**

Rhinitis and Asthma: linking diseases and treatments

Chairman: Michael Soyka

Join us on

Thursday April 28th

14.30–15.30h, Miles Davis Hall




Glenis Scadding

Exploring the link
between Rhinitis
and Asthma



Christian Virchow

Optimizing Asthma
control by treating
the upper airways



13:30–14:30

Salle Stravinski VI–VIII

Oral presentations SSAI: Allergology

Chairs: Kathrin Scherer Hofmeier, Basel; Peter Schmid–Grendelmeier, Zürich

13:30–13:42

Impact of antibody binding and epitope structure on the allergic reaction

M Vogel, F Zabel, E Keller, GT Jennings, MF Bachmann; Bern, Zürich

13:42–13:54

IgE-immune complexes differentially activate B cells and monocytes by FcεRII (CD23) cross-linking

P Engeroff, M Fellmann, M.F. Bachmann, M Vogel; Bern

13:54–14:06

Intradermal skin test reactivity to wasp and bee venom correlates to venom-specific IgE and decreases during venom-specific immunotherapy

I Saulite, W Hötzenecker, E Guenova, P Schmid–Grendelmeier, M Glatz; Zürich, Riga (LV)

14:06–14:18

Regulation of Apoptosis in Human Basophils upon FcεRI cross-linking

L Rohner, B Hagmann, A Odermatt, M Fux; Bern

14:18–14:30

Immunoglobulin deficiency in patients with chronic rhinosinusitis: Systematic review of the literature and meta-analysis

A J-P Schwitzguébel, P Jandus, J-S Lacroix, JD Seebach, T Harr; Genève

13:30–14:30

Salle Miles Davis IV

Symposium Aerobiology and allergies: From symptoms to allergens

Chairs: Pierre Gumowski, Meyrin;

Bernard Clot, Payerne, SSAI Honorary Member 2016

Introduction

Investigating respiratory allergies: more than just testing allergens.

Allergen sources and production

Måns Österberg, Ängelholm, SE

Indoor allergic symptoms and sensitivity are modulated by other environmental conditions such as endotoxin exposure

Olivier Michel, Brussels, BE

Discussion

Concluding remarks and session closure

Annual Congress

Swiss Society for Allergology
and Immunology

Jahresversammlung

der Schweizerischen Gesellschaft für
Allergologie und Immunologie

Assemblée annuelle

de la Société Suisse d'Allergologie
et d'Immunologie

**10 YEARS
XOLAIR**

Satellite Symposium

10 YEARS OF OMALIZUMAB
Proven drug and new opportunities

Thursday April 28th, 2016
14:30 - 15:30

Music and Convention Center Montreux
Saal Stravinsky VI-VIII

Thursday, April 28th, 2016

14:30–15:30
Miles Davis Hall

Rhinitis and Asthma: linking diseases and treatments

Chair: Michael Soyka, Basel

Exploring the link between Rhinitis and Asthma

Glenis Scadding, London, UK

Optimizing Asthma control by treating the upper airways

Christian Virchow, Rostock, DE

Symposium organized by **MEDA**

14:30–15:30
Salle Stravinski VI–VIII

10 years of Omalizumab: Proven drug and new opportunities

Chair: François Spertini, Lausanne

Xolair in Severe Allergic Asthma – 10 years of experience: Learnings and Highlights

Peter Schmid-Grendelmeier, Zürich

Xolair in Chronic Spontaneous Urticaria – Established drug in a different therapeutic setting

Barbara Ballmer-Weber, Luzern

Panel discussion

**What are our experiences with Xolair in severe allergic asthma
and how can they be useful for chronic spontaneous urticaria?**

Philip Tamarcaz, Genève; Wolfram Hötzenecker, Zürich;
Dagmar Simon, Bern

Symposium organized by  **NOVARTIS**

14:30–15:30
Salle Stravinski II–V

Clinical Symposium SSAI – Progress in vaccinology

Chairs: Burkhard Ludewig, St.Gallen; Martin Bachmann, Bern

14:30–15:00

Pneumococcal vaccine for whom?

Christoph Berger, Zürich

15:00–15:30

Immunotherapeutic approach of HPV associated diseases – an overview

Sjoerd H. Van der Burg, Leiden, NL

4 RHINO

4-Phasen-Rhinomanometer



www.rhinolab.com

MESSEN statt schätzen des nasalen Strömungswiderstandes

- Visuelle Erkennung der gestörten Funktion der Nasenklappe
- Digitale Sensoren, 3.000 Messpunkte in wenigen Sekunden erfasst
- Einführung von neuen und validierten logarithmischen Parametern
- Hohe Korrelation zwischen Messwerten und subjektivem Obstruktionsgefühl
- Validierte klinische Klassifikation des Nasenwiderstandes

Das Ergebnis umfangreicher Grundlagenforschung, ausgereifter digitaler Technik und jahrelanger klinischer Erfahrung!

Rhinolab
PROGRESS IN RHINOLOGY

Anklin

14:30–15:30
Salle Miles Davis V

Research Symposium SSAI – Leukemia & Lymphoma

Chairs: Anne Müller, Zürich; Margot Thome, Lausanne

14:30–15:00

Role of B-Cell receptor signaling in the pathogenesis of B-Cell Lymphoma

Georg Lenz, Münster, DE

15:00–15:30

Post-transcriptional and epigenetic regulation of diffuse large B-cell lymphomagenesis

Anne Müller, Zürich

15:00–16:00
Salle Miles Davis IV



General assembly SSA (Aerobiology)

15:30–16:30

Coffee break in the industrial exhibition

15:30–16:30
Foyer Miles Davis

Posterviewing SSORL

16:00–17:30
Salle Stravinski II-V

Clinical Symposium SSAI – Asthma and rhinitis

Chairs: Benjamin Marsland, Lausanne;
Andreas Bircher, Basel, SSAI Honorary Member 2015

16:00–16:20

Role of double-stranded DNA in allergic airway inflammation

Thomas Marichal, Liège, BE

ACTERIA Prize Winner 2015

Early Career Research Prize in Allergy

16:20–16:40

WHEAT – friend or foe?

Sandra Wieser (Pahr), Wien, AT

ACTERIA Prize Winner 2015

Doctoral Prize in Immunology

16:40–17:10

Type 2 inflammation and remodeling in chronic rhinosinusitis

Atsushi Kato, Chicago, US

17:10–17:30

Asthma endotypes and specific therapeutic approaches

Ian Pavord, Leicester, UK



Innovating respiratory medicine. By joining our forces.

We work passionately at the forefront of **respiratory medicine** to provide patients the best possible support. Our **innovative research** is the basis for new, groundbreaking therapies and **personalized healthcare concepts**. Not just treating symptoms, but in the long-term defeating diseases: this is not just a dream, it is our goal.

www.roche-pharma.ch



Roche Pharma (Switzerland) Ltd
4153 Reinach

16:00–17:30
Salle Miles Davis V

Research Symposium SSAI – Phagocytes in health and disease

Chairs: Manfred Kopf, Zürich; Beat Imhof, Genève

16:00–16:30

Development of tissue macrophages

Elisa Gomez Perdiguero, Paris, FR

16:30–17:00

MicroRNA control of tumor-associated macrophages

Michele De Palma, Lausanne

17:00–17:30

Neutrophil–Vessel Wall Interactions In Vivo: Mode, Mechanisms And Pathogenesis

Sussan Nourshargh, London, UK

16:30–17:30
Miles Davis Hall

Oral presentations III SSORL

Chairs: Philippe Pasche, Lausanne; Thomas Schweri, Biel/Bienne

16:30–16:40

Die CHOLE-Klassifikation: Eine retrospektive Studie zur Klassifikation von Mittelohrcholesteatomen

*Milici N, Shankar S, Linder T; Luzern

16:40–16:50

Experimentelles Bogengangsmode für die Simulation von Repositionsmanövern bei BPLS

*Zamaro E, Obrist D, Nienhaus A, Kalla R, Vibert D, Caversaccio M, Strupp M, Mantokoudis G; Bern, München (DE)

16:50–17:00

Perception : simultanéité cochléo-vestibulaire

*Todic J, Guyot J-P, Perez Fornos A, Cavuscens S, Ranieri M, Van der Berg R, Kingma H, Merfeld D, Lewis R, Guinand N; Genève

17:00–17:10

Restauration du réflexe vestibulo-colique au moyen de l'implant vestibulaire

*Liard Y, Cavuscens S, Ranieri M, van de Berg R, Kingma H, Guyot J-P, Perez Fornos A, Guinand N; Genève

17:10–17:20

Somatic tinnitus prevalence and treatment with tinnitus retraining therapy.

*Ostermann K, Lurquin P, Horoi M, Cotton P, Hervé V, Thill MP; Fribourg. Bruxelles (BE)

17:20–17:30

Tympanoplastik: Faszie oder Knorpel?

Rast C, Mantei T, Metternich FU; Aarau

17:30–18:30
Miles Davis Hall



Informationen aus dem Vorstand SSORL

...denn zu Hause
ist es doch
am schönsten!



Subkutanen Immunglobulin

- ✈ **Geringe systemische Nebenwirkungen im Vergleich zu IVIG¹**
- ✈ **Hohe Lebensqualität für Patienten dank mehr Unabhängigkeit und Flexibilität²**
- ✈ **Weniger Fehlzeiten in Schule und Beruf³**

Referenzen: **1.** Chapel HM et al. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000; 20(2): 94-100. **2.** Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs 2007; 21(2): 105-16. **3.** Fasth A & Nyström J. Quality of Life and Health-Care Resource Utilization among Children with Primary Immunodeficiency Receiving Home Treatment with Subcutaneous Human Immunoglobulin. J Clin Immunol 2008; 28(4): 370-378.

Subcuvia®

Z: Immunglobulin vom Menschen (SC/IMig) 160 mg/ml (16 %-ige Lösung). Protein mit $\geq 95\%$ Immunglobulin. Verteilung der IgG Subklassen: IgG1 45-75 %; IgG2 20-45 %; IgG3 3-10 %; IgG4 2-8 %. IgA-Gehalt: ≤ 4.8 mg/ml. Hilfsstoffe: Glycin, Natriumchlorid, Wasser für Injektionszwecke. **I/A:** Substitutionstherapie: Bei Primären Immunglobulinmangelkrankheiten. Bei Myelom oder chronisch lymphatischer Leukämie (CLL) mit schwerer sekundärer Hypogammaglobulinämie und rezidivierenden Infekten. Für alle Altersgruppen inkl. Kinder. **D:** Die Dosierung und Dosierungsintervalle sind abhängig von der Indikation sowie von der pharmakokinetischen und klinischen Reaktion. Die Dosierung sollte so eingestellt werden, dass ein IgG-Plasmaspiegel von mindestens 4-6 g/l aufrechterhalten werden kann. Subkutane, in Ausnahmefällen auch intramuskuläre, Verabreichung. **KI:** Überempfindlichkeitsreaktionen gegen einen der Inhaltsstoffe. Keine intravaskuläre Verabreichung. Bei schwerer Thrombozytopenie bzw. anderen Gerinnungsstörungen darf Subcuvia nicht i.m. verabreicht werden. **VM:** Wenn Subcuvia versehentlich in ein Blutgefäß verabreicht wird, kann der Patient einen Schock entwickeln. Patienten unter Heimselbstbehandlung und/oder deren Pflegepersonal müssen im Erkennen von frühen Anzeichen selten auftretender hypotensiver Reaktionen geschult sein. **IA:** Die Verabreichung von Immunglobulin kann die Wirkung von Impfstoffen beeinträchtigen. **UW:** Häufig (≥ 1 bis <10 %): An der Injektionsstelle: Blutung, Schmerzen, Hämatom, Erythem. Schüttelfrost. Selten können Immunglobuline vom Menschen einen plötzlichen Blutdruckabfall oder anaphylaktische Reaktionen verursachen, auch wenn der Patient bei früheren Anwendungen keine Reaktion gezeigt hat. Echte Überempfindlichkeitsreaktionen sind selten und können vor allem in den sehr seltenen Fällen von IgA-Mangel mit anti-IgA Antikörpern auftreten. **P:** Packungsgrößen: 1 x 5 ml, 20 x 5 ml, 1 x 10 ml und 20 x 10 ml. Abgabekategorie **B.** Kassenzulässig. Stand der Information: Dezember 2014. Weitere Informationen: siehe Fachinformation (www.swissmedinfo.ch) oder Baxalta Schweiz AG, 8604 Volketswil (www.baxalta.com).

17:30–18:30

Salle Stravinski II–V

Future investigators meeting SSAI

supported by the ACTERIA Foundation

Chairs: Greta Guarda, Lausanne; Annette Oxenius, Zürich

17:30–18:00

ERC funding opportunities for young PIs

Anne-Emmanuelle de Crousaz, Lausanne

18:00–18:30

Research Assessment: the tail is wagging the dog

Bernd Pulverer, Heidelberg, DE

17:30–19:00

Salle Stravinski VI–VIII



General assembly SSAI

From 19:30

Social dinner

	Miles Davis Hall	Salle Stravinski VI–VIII	Salle Stravinski II–V
08:00 – 08:30	Oral presentations IV SSORL 32	Clinical Symposium SSAI Autoimmunity and inflammation 32	Research Symposium SSAI High throughput approaches in basic/clinical research and diagnostics 33
08:30 – 09:00			
09:00 – 09:30			
09:30 – 10:00	Coffee break in the industrial exhibition		
10:00 – 10:30	Joint plenary session II Cancer immunity; head & neck 33		
10:30 – 11:00			
11:00 – 11:30			
11:30 – 12:00	Lunch in the industrial exhibition		
12:00 – 12:30			
12:30 – 13:00	Oral presentations V SSORL 35	Oral presentations SSAI Clinical Immunology 37	Oral presentations SSAI Basic Immunology II: Immunomodulatory mechanisms, B cells 35
13:00 – 13:30			
13:30 – 14:00	Satellite Symposium Vifor AG 38	Satellite Symposium ALK AG 38	Diagnostic Laboratory Symposium SSAI 38
14:00 – 14:30			
14:30 – 15:00	Coffee break in the industrial exhibition		
15:00 – 15:30	Joint plenary session III Mucosal immunity & bacterial/viral infections 39		
15:30 – 16:00			
16:00 – 16:30			
16:30 – 17:00	Joint award session 39		

Joint SSORL/SSAI

Satellite Symposium

Break

SSORL

SSAI

Salle Miles Davis V	Salle Miles Davis IV	Foyer Miles Davis	
		Poster exhibition	08:00 - 08:30
			08:30 - 09:00
			09:00 - 09:30
Coffee break in the industrial exhibition			09:30 - 10:00
			10:00 - 10:30
			10:30 - 11:00
			11:00 - 11:30
Lunch in the industrial exhibition		Posterwalk SSAI	11:30 - 12:00
		33	12:00 - 12:30
Oral presentations SSAI Basic Immunology III: T cell selection, activation, effector function	eHealth	Poster exhibition	12:30 - 13:00
37	38		13:00 - 13:30
Research Symposium SSAI T-cell regulation			13:30 - 14:00
39			14:00 - 14:30
Coffee break in the industrial exhibition			14:30 - 15:00
			15:00 - 15:30
			15:30 - 16:00
			16:00 - 16:30
			16:30 - 17:00



Simultaneous translation DE/FR

Industrial exhibition: Foyer Accueil Stravinski

AV-Check: Salle Stravinski I

Meetings: please refer to separate meeting list on page 41

08:00–09:30

Miles Davis Hall

Oral presentations IV SSORL

Chairs: Sandro Stöckli, St.Gallen; Michael Soyka, Zürich

08:00–08:10

Assessment of failure and complication rate of transtracheal jet ventilation in a cohort of patients with head and neck tumors

*Haller C, Jacomet A, Gabi K, Stöckli S, Broglie MA; St. Gallen

08:10–08:20

Diagnostic challenge of sinonasal lymphoma

*Kiessling SY, Soyka MB, Huber, GF, Holzmann D, Laske RD; Zürich

08:20–08:30

Endoscopic skull base training using 3D printed models with pre-existing pathology

Brand Y, Prepageran N, Waran V; Basel, Kuala Lumpur (MY)

08:30–08:40

Microvascular coupler in free flap head and neck reconstruction surgery.

Timochenko A, Asanau A, Colin V; St-Etienne (FR)

08:40–08:50

Outcome and impact of high-risk human papillomavirus in patients treated with primary surgery for oropharyngeal cancer

Broglie MA, Stoeckli SJ, Pasche P, Reinhard A, De Leval L, Huber GF, Pezier TF, Soltermann A, Giger R, Arnold A, Diamantis E, Arnoux A, Mueller M, Spreitzer S, Lang F, Lutchmaya M, Stauffer E, et al.; St.Gallen, Lausanne, Zürich, Berne

08:50–09:00

PEG Analyse bei primär radiochemotherpierten HNO Patienten

*Schoch M, Albrecht F, Henke G, Sulz M, Stöckli SJ, Broglie MA; St.Gallen

09:00–09:10

Pituitary surgery and volumetric assessment of extent of resection: a paradigm shift in the use of intraoperative MRI

Holzmann D, Serra C, Pangalu A, Valavanis A, Schmid C, Regli L; Zürich

09:10–09:20

Platelet rich plasma and adipose stem cells, an innovative approach for the treatment of head and neck lymphedema

*Erba P, Konerding MA, Raffoul W, Ackermann M; Bern, Lausanne, Mainz (DE)

09:20–09:30

Should the neck in sinonasal undifferentiated carcinoma (SNUC) be treated in patients without evidence of regional metastasis? Case-series, systematic review and meta-analysis

Morand GB, Vital D, Huber GF, Holzmann D, Soyka MB; Zürich

08:00–09:30

Salle Stravinski VI–VIII

Clinical Symposium SSAI – Autoimmunity and inflammation

Chairs: Thomas Hauser, Zürich; Carole Bourquin, Fribourg

08:00–08:30

Autoimmune disorders of the inner ear

Daniel Bodmer, Basel

08:30–09:00

An overview of the mechanisms of the prototypic AID

Isabelle Touthou, Montpellier, FR

09:00–09:30

Sjögren's syndrome, potential therapies

Alain Saraux, Brest, FR

08:00–09:30

Salle Stravinski II-V

Research Symposium SSAI – High throughput approaches in basic/clinical research and diagnostics

Chairs: Hans Acha-Orbea, Lausanne; Walter Reith, Genève

08:00–08:30

High throughput proteomic phenotyping of clinical specimens

Ruedi Aebersold, Zürich

08:30–09:00

Immunogenetics, from genome-wide association study to gene function

Pierre-Yves Bochud, Lausanne

09:00–09:30

Molecular and metabolic networks regulating immune cell function

Giulio Superti-Furga, Vienna, AT

09:30–10:00

Coffee break in the industrial exhibition

10:00–11:30

Miles Davis Hall

Joint plenary session II – Cancer immunity; head & neck

Chairs: Philippe Pasche, Lausanne; George Coukos, Lausanne

10:00–10:30

Immunology and Immunotherapy of Head and Neck Cancer

Christian Simon, Lausanne

10:30–11:00

Immunotherapy based on overcoming functional barriers within the tumor microenvironment

Thomas F. Gajewski, Chicago, US

11:00–11:30

On the role of neo- and viral antigens in cancer immunotherapy

John Haanen, Amsterdam, NL

11:30–12:30

Foyer Miles Davis

Posterwalk SSAI

Basic Immunology – Group II: P19–P34

Chairs: Fabio Martinon, Lausanne; Thierry Roger, Lausanne

Clinical, laboratory and translational immunology – Group II: P54–P69

Chairs: Carlo Chizzolini, Genève; Stephan von Gunten, Bern

Allergology / Case reports in allergology: P70–P75

Chairs: Giovanni Ferrari, Bellinzona; Wolfram Hötzenecker, Zürich; Peter Schmid-Grendelmeier, Zürich

11:30–12:30

Lunch in the industrial exhibition



ALK Satellite Symposium, April 29th, 2016 1:30 – 2:30 pm Salle Stravinski VI-VIII

ALK House Dust Mite SLIT Tablet –
a new level of evidence in the treatment
of allergic rhinoconjunctivitis and
allergic asthma.



12:30–13:30

Miles Davis Hall

12:30–12:40

12:40–12:50

12:50–13:00

13:00–13:10

13:10–13:20

13:20–13:30

Oral presentations V SSORL

Chairs: Christian Simon, Lausanne; Ruth Köppl, Basel

Cancer of Unknown Primary (CUP): an institutional experience over the last decade regarding the influence of p16 status

*Schlumpf MF, Gsponer JR, Haerle SK; Basel, Luzern

Inhibition of mTOR by Rapamycin Results in Auditory Hair Cell Damage and Decreased Spiral Ganglion Neuron Outgrowth and Neurite Formation In Vitro

*Leitmeyer K, Glutz A, Radojevic V, Setz C, Huerzeler N, Bumann H, Bodmer D, Brand Y; Basel

First animal model of extracapsular spread using orthotopic transplantation of squamous cell carcinoma lymph node micro-metastasis in immunocompetent mice

*Mermod M, Petrova TV, Simon Ch, Tolstonog, G, Monnier Y; Lausanne

Prediction of occult lymph node metastasis in squamous cell carcinoma of the oral cavity and the oropharynx using peritumoral PROX1 lymphatic nuclear quantification

*Mermod M, Bongiovanni M, Petrova TV, Dubikovskaya EA, Simon Ch, Tolstonog G, Monnier Y; Lausanne

Tumor-derived exosomes regulate expression of immune function-related genes in human T-cell subsets

Muller L, Mitsuhashi M, Simms P, Gooding WE, Whiteside TL; Basel, Pittsburgh (US), Irvine (US), Maywood (US)

Verbesserte zelluläre Aufnahme von modifizierten rekombinanten Allergenen (MAT-Fel d 1)

Soyka MB, Rhyner C, Zaleksa A, Eiwegger T, Bekpen C, Akdis M, Crameri R, Akdis CA; Davos, Zürich

12:30–13:30

Salle Stravinski II-V

12:30–12:42

12:42–12:54

12:54–13:06

13:06–13:18

13:18–13:30

Oral presentations SSAI: Basic Immunology II

Immune regulatory mechanisms, B cells

Chairs: Daniela Finke, Basel; Sanjiv Luther, Lausanne

Lymphotoxin- β receptor signalling regulates self-renewal during stress induced hematopoiesis

S Hoepner, D Korner, C Riether, A.F. Ochsenbein; Bern

The maternal microbiota drives postnatal innate immune development

SC Ganai-Vonarburg, M Gomez de Agüero, T Fuhrer, S Rupp, U Sauer, KD McCoy, AJ Macpherson; Bern, Zürich

NLR5 shields T lymphocytes from NK-cell-mediated elimination under inflammatory conditions

K Ludigs, C Jandus, DT Utzschneider, F Staehli, S Bessoles, A Dang, G Rota, W Castro, D Zehn, E Vivier, W Held, P Romero, G Guarda; Lausanne, Marseille (FR)

Permissive roles of Flt3-ligand and Interleukin-7 in B cell development

P Tsapogas, AL von Münchow, LI Alberti Servera, A Rolink; Basel

Infection-Induced Alterations of CD4+ T Cell Responses upon Heterologous Challenge

N Rakebrandt, K Littringer, N Joller; Zürich



SGORL / SGAI SYMPOSIUM MONTREUX

Synergy between phytotherapy and psychotherapy - the solution for tinnitus ?

Friday, 29 April 2016
1.30 – 2.30 pm
Miles Davis Hall (Plenum 1)

AGENDA

1.30 – 1.55 pm

Rational tinnitus therapy

Associate Professor, Dr **Andreas Schapowal**,
Specialist in ENT, Landquart

1.55 – 2.20 pm

Tinnitus: the psychiatric perspective

Dr **Rahul Gupta**, Specialist in Psychiatry
and Psychotherapy
Co – Director of Medicine PDGR, Cazis

2.20 – 2.30 pm

Discussion

12:30–13:30
Salle Miles Davis V

Oral presentations SSAI: Basic Immunology III

T cell selection, activation, effector function

Chairs: Silvia Monticelli, Bellinzona; Werner Held, Lausanne

12:30–12:42

Molecular profiling of CD8 T cells from autochthonous melanoma identifies Maf as driver of T cell exhaustion

M Giordano, C Henin, C Imbratta, J Maurizzio, D Speiser, AM Schmitt-Verhulst, G Verdeil; Lausanne, Marseille (FR)

12:42–12:54

Determining the pMHC threshold required for CD8+ T cell expansion after dendritic cell vaccination

J Abe, P Germann, J Ripoll, J Sharpe, JV Stein; Bern, Barcelona (ES), Madrid (ES)

12:54–13:06

STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.

O Demaria, J Di Domizio, M Gilliet; Lausanne

13:06–13:18

The GTPase-activating protein Myo9b controls resident memory T cell function by enabling barrier-crossing motility

F Moalli, B Stolp, M Bähler, R Lyck, JV Stein; Bern, Münster (DE)

13:18–13:30

The role of lymph node fibroblasts in immune regulation

K Schäuble, S Favre, F Alfei, D Zehn, SA Luther; Lausanne, Munich (DE)

12:30–13:30
Salle Stravinski VI–VIII

Oral presentations SSAI: Clinical Immunology

Chairs: Lionel Arlettaz, Sion; Ingmar Heijnen, Basel

12:30–12:42

High dimensional analysis of melanoma-specific immune responses.

C Krieg, F Hartmann, S Schindler, R Dummer, M Levesque, L French, S Guglietta, L Weber, M Robinson, B Becher; Zürich, Milan (IT)

12:42–12:54

Dissecting the impact of peptide-MHC and TCR-pMHC binding strengths on the functional avidity of tumor-specific CD8 T cells

P Baumgartner, M Hebeisen, CM Costa-Nunes, N Bordry, J Schmidt, P Guilaume, IF Luescher, N Rufer, DE Speiser; Lausanne

12:54–13:06

Seroprevalence of antibodies to Chlamydia trachomatis is not increased in women with Systemic Lupus Erythematosus – a case-control study.

A Santos, G Greub, S Aeby, D Wunder, G Pantaleo, C Ribi; Lausanne

13:06–13:18

Isolation and characterization of hypocretin-reactive CD4+ T cells in narcoleptic patients

D Latorre, E Armentani, U Kallweit, M Manconi, R Khatami, C.L. Bassetti, F Sallusto; Bellinzona, Bern, Lugano, Barmelweid

13:18–13:30

Addressing the complexity of antigen specific CD4+ T cell responses in cancer patients

C Costa-Nunes, C Jandus, P Baumgaertner, P Sousa-Alves, F Sandoval, O Adotévi, D Speiser, P Romero; Lausanne, Brussels (BE), Besançon (FR)

Friday, April 29th, 2016

12:30–13:30
Salle Miles Davis IV

eHealth – Are you ready?

Adrian Schmid, Bern; Petra Felder, Bern; Katrin Brunner, Bern

13:30–14:30
Miles Davis Hall



Synergie durch Phytotherapie und Psychotherapie – die Lösung bei Tinnitus?

13:30–13:55

Rationale Tinnitustherapie
Andreas Schapowal, Landquart

13:55–14:20

Tinnitus: die psychiatrische Perspektive
Rahul Gupta, Cazis

14:20–14:30

Diskussion

Satellite Symposium organized by  **Vifor Pharma**

13:30–14:30
Salle Stravinski VI–VIII

ALK House Dust Mite SLIT Tablet – a new level of evidence in the treatment of allergic rhinoconjunctivitis and allergic asthma.

Jörg Kleine-Tebbe, Berlin, DE

Satellite Symposium organized by  **ALK**

13:30–14:30
Salle Stravinski II–V

Diagnostic laboratory symposium

Chairs: Onur Boyman, Zürich; Eric Dayer, Sion, SSAI Honorary Member 2015

13:30–13:50

In vitro diagnosis of celiac disease
Claude Olivier Marti, Fribourg

13:50–14:10

How to explore complement defects
Salima Sadallah, Lausanne

14:10–14:30

Usefulness of anti-C1q determination
Marten Trendelenburg, Basel

13:30–14:30
Salle Miles Davis V

Research Symposium SSAI – T-cell regulation

Chair: Federica Sallusto, Bellinzona; Jens Stein, Bern

13:30–13:50

Affinity rules! Even for Tregs

Ed Palmer, Basel, SSAI Honorary Member 2015

13:50–14:10

Linking functional diversity and level of TCR stimulation in chronic infections

Dietmar Zehn, Lausanne

ACTERIA Prize Winner 2015

Early Career Research Prize in Immunology

14:10–14:30

Physiological consequences of altered aryl hydrocarbon receptor feedback responses in the immune system

Chris Schiering, London, UK

ACTERIA Prize Winner 2015

14:30–15:00

Coffee break in the industrial exhibition

15:00–16:30
Miles Davis Hall

Joint plenary session III – Mucosal immunity & bacterial/viral infections

Chairs: Antje Welge-Lüssen, Basel; Daniel Pinschewer, Basel

15:00–15:45

The Role of Taste Receptors in Upper Airway Innate Immunity

Noam A. Cohen, Pennsylvania, US

15:45–16:30

Immunity to Tuberculosis: From Bench to Bush and Back to Bench

Stefan H. E. Kaufmann, Berlin, DE

16:30–17:00
Miles Davis Hall

Joint award session

Dymista®

faster and
more effective
in seasonal
allergic rhinitis¹

visit us
at stand nr 50



1. Compared vs. intranasal fluticasone propionate and azelastine hydrochloride.

Meltzer E et al. Clinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysis. Int Arch Allergy Immunol 2013; 161(4):369-377.

MEDA

Dymista® Nasenspray (Azelastinhydrochlorid/Fluticasonpropionat): Antihistaminikum/Corticosteroid. **Indikationen:** Saisonale allergische Rhinitis und Rhinokonjunktivitis. **Dosierung:** Ab 12 Jahren: 1 Sprühstoss (0,14 mg Azelastinhydrochlorid/0,05 mg Fluticasonpropionat) pro Nasenloch 2x täglich. **Kontraindikationen:** Überempfindlichkeit gegen Inhaltsstoffe. **Warnhinweise und Vorsichtsmassnahmen:** Nasale Corticosteroide in hohen Dosen über einen längeren Zeitraum verwendet, können systemische Effekte haben wie z.B. Cushing-Syndrom, Wachstumsverzögerung, Katarakt oder Glaukom. Schwangerschaft: nur wenn klar notwendig. Stillzeit: nicht empfohlen. **Interaktionen:** Hoch potente Inhibitoren des Cytochrom-P450 3A4-Systems wie z.B. Rifonavir. **Unerwünschte Wirkungen:** Kopfschmerzen, Dysgeusie, Epistaxis, nasale Beschwerden (Stechen, Juckreiz), Niesen, Nasentrockenheit, Husten, Halstrockenheit, Halsreizung. (UW < 0,1% siehe AIPS). **Packungen:** Nasenspray 17 ml. **(B). Kassenzulässig.** Ausführliche Informationen: Packungsbeilage, AIPS (www.swissmedinfo.ch) oder MEDA Pharma GmbH, 8602 Wangen-Brüttisellen. Stand der Information: Januar 2013.



Swiss Society of Oto-Rhino-Laryngology, Head and Neck Surgery | SSORL

Sitzung SGORL Prüfungskommission	27.04.2016, 10:00-17:00 h Grand Hotel Suisse Majestic
Sitzung SGORL Arbeitsgruppe Ultraschall	28.04.2016, 12:30-13:30 h Salle Miles Davis III
Sitzung SGORL Arbeitsgruppe Pädiatrische ORL	28.04.2016, 12:30-13:30 h Bureau Stravinsky VI
Sitzung SGORL Arbeitsgruppe Plastische Gesichtschirurgie	28.04.2016, 12:30-13:30 h Salle Miles Davis I
Sitzung SGORL Arbeitsgruppe ONO	28.04.2016, 15:30-17:00 h Salle Miles Davis I
Infos aus dem Vorstand	28.04.2016, 17:30-18:30 h Miles Davis Hall

Swiss Society for Allergology and Immunology | SSAI

Board Meeting SSAI - Part I	27.04.2016, 17:00-19:30 h Grand Hotel Suisse Majestic; Room Chablais
Board Meeting SSAI - Part II	28.04.2016, 12:30-13:30 h Bureau Stravinsky V
General Assembly SSAI	28.04.2016, 17:30-19:00 h Salle Stravinsky II-III
Sitzung CLD Laborkommission	29.04.2016, 11:30-13:30 h Bureau Stravinsky V

Swiss Association for Aerobiology | SSA

General Assembly SSA	28.04.2016, 15:00-16:00 h Salle Miles Davis IV
----------------------	---

Intratect[®] 5% et Intratect[®] 10%

Immunglobuline humaine pour l'administration intraveineuse (IgIV)

La confiance dans la qualité



- Substitution d'anti-corps* et immunomodulation** ¹⁾
- Solutions d'IgIV à 5% et à 10% d'une seule source
- Solution 10% pour perfusion rapide (jusqu'à 8 ml/kg pc/h*) ¹⁾

*p. ex. : DIP ** PTI, SGB, maladie de Kawasaki ¹⁾ voir l'information professionnelle : www.swissmedinfo.ch

Intratect[®] 5% / Intratect[®] 10%. C: immunoglobuline humaine (≥96% d'IgG) pour l'administration intraveineuse (IgIV). Solution à 5% (50 mg/ml) / 10% (100 mg/ml) de protéine plasmatique. Pour plus d'informations, voir l'information professionnelle. **I:** traitement de substitution lors de syndromes de déficit immunitaire primitif (DIP) et myélome ou leucémie lymphoïde chronique avec hypogammaglobulinémie secondaire sévère et infections à répétition, infections récidivantes chez l'enfant atteint de SIDA congénital, traitements immunomodulateurs chez l'adulte ou l'enfant lors de purpura thrombopénique idiopathique (PTI) en cas de risque hémorragique important ou avant un acte chirurgical pour corriger le taux des plaquettes, syndrome de Guillain-Barré (SGB), maladie de Kawasaki, hypogammaglobulinémie lors de greffe de cellules souches hématopoïétiques (GCSH). **P:** la posologie, la fréquence de l'application et la vitesse d'infusion dépendent de l'indication. Pour plus d'informations, voir l'information professionnelle. **Ci:** hypersensibilité à un quelconque composant du produit ou aux immunoglobulines homologues en cas de déficit en IgA lorsque le patient présente des anticorps contre l'immunoglobuline A. **PE:** ne pas diluer ou mélanger avec d'autres médicaments. Respecter la vitesse de perfusion. Certains EI sévères peuvent être liés à la vitesse de perfusion. Maintenir une vitesse de perfusion aussi lente que possible et un dosage aussi bas que possible pour les patients traités pour la première fois par IgIV, présentant un risque de dysfonctionnement rénal ou d'événements thromboemboliques. Une hydratation appropriée doit être assurée avant de commencer la perfusion. Surveiller les patients pendant et après la perfusion. En cas d'EI, il faut soit réduire la vitesse de perfusion, soit interrompre la perfusion. Traitement symptomatique des EI. Eviter l'utilisation simultanée de diurétiques de l'anse. Pour plus d'informations, voir l'information professionnelle. **IA:** altération possible des effets de vaccins et des analyses sérologiques. **GA:** seulement après évaluation du rapport bénéfice/risque. Pour plus d'informations, voir l'information professionnelle. **EI** les plus fréquents: Intratect 5%: céphalées, fièvre. Intratect 10%: céphalées, sensation de malaise, palpitations, réactions liées à la perfusion, douleurs articulaires, dorsalgies, douleurs osseuses. Cas isolés de méningite aseptique, d'anémie hémolytique/hémolyse réversibles, réactions d'hypersensibilité pouvant aller jusqu'au choc et réactions cutanées. Pour plus d'informations, voir l'information professionnelle. **E:** solution d'infusion Intratect 5%: 20, 50, 100 et 200 ml. Intratect 10%: 10, 50, 100 et 200 ml. **Catégorie de vente:** B (admis par les caisses-maladie (limitatio)). Pour plus d'informations, www.swissmedinfo.ch. **Biotest (Suisse) SA, Rapperswil, www.biotest.ch.**

Posters SSAI

(posters with additional speed abstract presentation are marked with *)

Basic Immunology I – Group I

Posterdiscussion SSAI | Thursday, April 28th, 2016 | 12:30 – 13:30

- P01*** High prevalence of isotype-switched antibody response against carbohydrate structures
C Schneider, M Wehrli, DF Smith, RD Cumming, A Straumann, M Lötscher, A Zürcher, S von Gunten; Bern, Atlanta (US), Olten, Bern
- P02** Induction and dynamics of germinal center responses in mice after immunization with virus-like particles
CC Krüger, F Zabel, MF Bachmann; Bern, Zürich
- P03** Intestinal fibroblasts – Do they form a survival niche for IgA-producing plasma cells?
FN Renevey, S Siegert, C-Y Yang, J Bernier-Latmani, J Coca, NL Harris, TV Petrova, SA Luther; Lausanne
- P04** B cells initiate and maintain allergic responses via BCR-independent antigen presentation
T Wypych, A Lanzavecchia, F Sallusto; Bellinzona, Bern, Zürich
- P05** Epitope mapping and fine specificity of human antibody responses for novel candidate blood-stage malaria vaccine P27A
KM Geiger, D Guignard, S Houard, O Leroy, CMC Daubenberger, M Tanner, S Shekalaghe, S Abdulla, F Spertini, G Corradin, R Audran; Lausanne, Heidelberg (DE), Basel, Bagamoyo (TZ)
- P06** Role of follicular helper T cells and plasma cells in viral-vectored vaccination
FM de Souza Leoratti, N Valero-Pacheco, A El-Turabi, M Bachmann, E Atcheson, CJ Janse, SM Khan, A Reyes-Sandoval; Oxford (UK), Bern, Leiden (NL)
- P07** Differential dendritic cell activation in peripheral T cell tolerance
D Jaramillo, A Oxenius, R Spörri; Zürich
- P08** CD11b regulates susceptibility to CIA through suppression of IL-17
M Stevanin, V Chobaz, N Busso, L Zhang, H Acha-Orbea, D Ehrichiou; Lausanne, Baltimore (US)
- P09*** Autologous IL-10-DC promote regulatory CD4+ T cells and prolong rat-to-mouse islets xenograft survival
N Madelon, E Montanari, Y Muller, J Pimenta, L Gruaz, L Buhler, G Puga Yung, JD Seebach; Genève
- P10*** T cell priming ability by activated, Nlrp5-deficient DCs is unaffected despite partially reduced MHC1 levels
G Rota, K Ludigs, S Siegert, A Tardivel, L Morgado, W Reith, A De Gassart, G Guarda; Lausanne, Genève
- P11** Identification of C3 as a critical factor of innate and adaptive responses to poxvirus
J Delaloye, D Leroy, G Pantaleo, C Gomez, B Perdiguero, M Esteban, T Roger, T Calandra; Lausanne, Madrid (ES)
- P12*** CD4 T cells are required for both development and maintenance of intestinal inflammation in a new mouse model of reversible colitis
J Brasseit, E Steiner, M Faderl, W Kwong, N Corazza, M Noti, C Mueller; Bern
- P13** TREM-1 links dyslipidemia to inflammation and lipid deposition in atherosclerosis
D Zysset, B Weber, S Rihs, S Freigang, C Riether, Y Banz, A Cerwenka, C Simillion, P Marques-Vidalq, L Saurer, Ch Mueller; Bern, Heidelberg (DE), Lausanne

NOUS FÊTONS PLUS DE 400'000 ANNÉES-PATIENTS D'EXPÉRIENCE.¹



Le seul traitement anti-IgE contre l'asthme allergique.²

1. IMS PADDIS March 2015 2. www.ginasthma.org

XOLAIR® (Omalizumab). **Z:** Omalizumab; flacon de poudre contenant 150mg d'omalizumab et solvant pour solution injectable. **I:** *Asthme allergique*: traitement additionnel, pour améliorer le contrôle de l'asthme chez les adultes et les enfants (à partir de 6 ans) atteints d'asthme allergique persistant sévère (ayant un test cutané positif ou une réactivité *in vitro* contre un pneumallergène perannuel), et qui, malgré un traitement quotidien par un corticostéroïde inhalé à forte dose et un bêta₂-agoniste inhalé à longue durée d'action, présentent non seulement une réduction de la fonction pulmonaire (VEMS <80%) mais aussi des symptômes diurnes fréquents ou des réveils nocturnes et des exacerbations de l'asthme. *Urticaire chronique spontanée* (UCS): Traitement additionnel chez les adultes et les adolescents (à partir de 12 ans), dans l'UCS de longue durée*, non contrôlée par les antihistaminiques H1 et pour laquelle aucune autre affection sous-jacente n'a été identifiée dans le cadre d'un examen effectué par un médecin ayant de l'expérience dans ce type d'affections (* Les études d'enregistrement ont porté sur des patients atteints d'une UCS évoluant depuis 6 mois à 66 ans, en moyenne depuis 6 ans). **D:** *Asthme allergique: adultes et enfants à partir de 6 ans*: 75-600mg de XOLAIR® 1-2x/mois en fonction du taux sérique initial d'IgE (U.I./ml) et du poids corporel du patient. *Urticaire chronique spontanée: adultes et adolescents à partir de 12 ans*: dose initiale de 300mg sous forme d'une injection sous-cutanée toutes les 4 semaines. La plupart des patients qui répondent au traitement montrent déjà une amélioration dans les 4 semaines qui suivent la première dose. Réévaluer la nécessité du traitement à intervalles réguliers. Plus d'informations, voir www.swissmedinfo.ch. **C:** Hypersensibilité au principe actif ou à l'un des composants. **PR:** N'est pas indiqué pour le traitement des exacerbations aiguës de l'asthme, du bronchospasme aigu ou de l'état de mal asthmatique. N'a pas été étudié dans le syndrome d'hyperimmunoglobulinémie E, l'aspergillose broncho-pulmonaire allergique, la prévention de réactions allergiques, la dermatite atopique, la rhinite allergique, les allergies alimentaires, les maladies auto-immunes, les états dus à des complexes immuns, ni chez les patients avec insuffisance rénale ou hépatique préexistante. Réduction des corticostéroïdes sous surveillance médicale. Des réactions allergiques, des réactions anaphylactiques mettant en jeu le pronostic vital ou un choc anaphylactique peuvent survenir. Une maladie sérique et des symptômes du même type ont été rarement rapportés. Rarement syndrome de Churg-Strauss et syndrome hyperéosinophilique. Des problèmes en rapport avec une immunogénicité, des infections parasitaires (helminthiases), des affections malignes ou des événements thromboemboliques artériels (ATE) peuvent survenir. Plus d'informations, voir www.swissmedinfo.ch. **IA:** *Asthme allergique*: il n'a pas été mis en évidence de modification de la tolérance en cas d'administration de médicaments antiasthmatiques d'utilisation courante. L'efficacité du traitement en association avec une immunothérapie spécifique n'a pas été établie. *Urticaire chronique spontanée*: les antihistaminiques H2 et les LTRA n'ont pas eu d'influence importante sur la pharmacocinétique de l'omalizumab. Plus d'informations, voir www.swissmedinfo.ch. **E:** *Très fréquents*: pyrexie, céphalées. *Fréquents*: (rhino)pharyngite, douleurs de l'abdomen supérieur, douleurs, érythème, prurit, gonflement, sinusite, infections des voies respiratoires supérieures, infections des voies urinaires, douleurs sinusales, myalgies, douleurs des membres, douleurs musculosquelettiques, douleurs articulaires. *Occasionnels*: Vertiges, somnolence, paresthésies, syncope, hypotension orthostatique, bouffées vasomotrices, toux, bronchospasmes allergiques, nausées, diarrhées, dyspepsie, urticaire, éruption, prurit, photosensibilité, prise de poids, fatigue, gonflement des bras, symptômes grippaux. *Post-commercialisation*: anaphylaxie et réactions anaphylactoides, alopecie, thrombopénie idiopathique sévère, angéite granulomateuse allergique (syndrome de Churg-Strauss), arthralgies, myalgies, gonflements articulaires. *En outre*: tumeurs malignes, événements thromboemboliques artériels (ATE), diminution des thrombocytes, augmentation des taux sériques d'IgE totales, infections parasitaires. *Effets indésirables rares, très rares* et autres informations détaillées: www.swissmedinfo.ch. **P:** 1 flacon de 150mg d'omalizumab avec 1 ampoule de solvant de 2ml. Liste: B. Admis par les caisses-maladie. Pour plus d'informations, consulter www.swissmedinfo.ch. Novartis Pharma Schweiz AG, Risch; adresse: Saurstoffli 14, 6343 Rotkreuz, tél. 041 763 71 11 V8

- P14** **INTERFERing with the pathogenesis of Rosacea**
A Mylonas, O Demaria, AA Navarini, H Friedrich, S Meller, MF Gilliet, C Conrad;
Lausanne, Zürich, Duesseldorf (DE)
- P15** **CXCL12/HMGB1 synergy enhances lymphocyte migration**
L Spagnuolo, N Boss, C Hotz, M Uguccioni, C Bourquin; Fribourg, Bellinzona
- P16** **Pharmacological inhibition of PKC- θ controls birch pollen induced airway inflammation**
P Chenuet, F Madouri, L Fauconnier, T Marchiol, N Rouxel, A Ledru, F Erard, L Mascarell, F Trovero,
V Quesniaux, B Ryffel, D Togbe; Orléans (FR), Antony (FR)
- P17** **The AIM2 inflammasome is a guardian of Nuclear Envelope integrity**
J Lugin, A Di Micco, G Frera, Y Jamilloux, A Tardivel, A de Gassart, L Zaffalon, S Siegert,
M Quadroni, P Broz, T Henry and F Martinon; Lausanne, Lyon (FR), Basel
- P18** **Determining redundancy and function of Inhibitors of Apoptosis Proteins in hematopoiesis and inflammation**
J Knop, LM Spilgies, L Vasilikos, K Hänggi, WW Wong; Zürich

Basic Immunology – Group II

Posterdiscussion SSAI | Friday, April 29, 2016 | 11:30 – 12:30

- P19** **Infection-induced changes in regulatory T cells**
K Littringer, N Joller, N Rakebrandt; Zürich
- P20** **IRE1-XBP1 branch down-regulation as a novel marker for DLBCL classification**
B Bujisic, A De Gassart, S Chelbi, F Bertoni and F Martinon; Lausanne, Bellinzona
- P21** **T lymphocytes regulate myelopoiesis to induce immunosuppression in tumor bearing mice**
M Al Sayed, M Amrein, E Buehrer, AL Hugué, C Riether, A Ochsenbein; Bern
- P22** **Retention Integrins Mediate Anti-Tumor Immunity by Regulating the Migration of Tumor Resident CD8⁺ T Lymphocytes**
T Murray, S Fuertes Marraco, P Baumgartner, N Bordry, L Cagnon, A Donda, P Romero, G Verdeil,
D Speiser; Lausanne
- P23** **Modulation of immune cell trafficking into human colorectal cancer by gut microbiota**
E Cremonesi, F Amicarella, E Padovan, MG Muraro, V Mele, V Governa, P Zajac, D Oertli, JG Garzón,
L Borsig, G Iezzi; Basel, Zürich
- P24** **The impact of the Polycomb Repressive Complex 2 on thymic development and function**
HY Teh, C Mayer, T Barthlott, S Zuklys, G Holländer; Basel
- P25** **Foxn1 choreographs both early and late events in thymic lympho-stromal cross-talk**
S Zuklys, S Zhanybekova, C Mayer, HY Teh, K Hafen, T Barthlott, A Handel, C Ponting, G Holländer;
Basel, Oxford (UK)
- P26** **Tracing Thymic Epithelial Progenitor Cells**
CE Mayer, S Zuklys, I Ohigashi, HY Teh, N Shikama, S Sansom, Y Takahama, C Ponting, GA
Holländer; Basel, Tokushima (JP), Oxford (UK)

- P28** **Phosphatidylinositol localisation orchestrated by TTC7 defines cellular function**
A Mauracher, U Nuesch, S Vavassori, L Opitz, B Volkmer, J Pachlopnik-Schmid; Zürich
- P29** **Therapeutic IgG induce different phenotypic and functional changes in human NK cells in vitro and ex vivo.**
M Papaserafeim, GL Puga Yung, L Gruaz, R Spirig, C Vonarburg, P Jandus, JD Seebach; Genève, Bern
- P30** **Reduction of human NK cell recruitment to HLA-E/human CD46 double-transgenic pig tissue in a human whole-blood pig forelimb perfusion system**
G Puga Yung, N Madelon, AK Bongoni, A Pradier, M Papaserafeim, L Padayachy, L Gruaz, J Pimenta, DL Ayares, E Wolf, N. Klymiuk, MA Constantinescu, E Voegelin, D Kiermeir, HJ Jenni, R Rieben, JD Seebach; Genève, Bern, Blacksburg (US), Munich (DE)
- P31** **Characterization of Siglec-9+ and Siglec-9- natural killer (NK) cells**
KF Boligan, C Gallasz, C Schneider, S von Gunten; Bern
- P32** **Rapid Sequestration of Leishmania mexicana by Neutrophils Contributes to the Development of Chronic Lesion**
BP Hurrell, S Schuster, S Yousefi, H-U Simon, AJ Müller, F Tacchini-Cottier; Lausanne, Bern, Magdeburg (DE)
- P33** **Interleukin 33 and stromal cells in chronic viral infection**
S Kallert, HY Huang, M Lu, P Aparicio-Domingo, S Favre, M Löhning, D Merkler, SA Luther, DD Pinschewer; Basel, Epalinges, Genève, Berlin (DE)
- P34** **NLR5 deficiency confers partial resistance to murine leukemia virus infection**
W Castro, A Dang, L Morgado, G Guarda; Lausanne

Clinical, laboratory and translational immunology – Group I

Posterdiscussion SSAI | Thursday, April 28, 2016 | 12:30 – 13:30

- P35** **Flt3L controls the number of innate lymphoid cells in fetal and adult mice**
A Bärenwaldt, N von Burg, M Kreuzaler, S Sitte, E Horvath, A Peter, D Vöhringer, A Rolink, D Finke; Basel, Erlangen (DE)
- P36** **Surface expression of GM3(Neu5Gc) gangliosides under hypoxic conditions modulates the tumor-directed immune response.**
D Dorvignit, KF Boligan, L García-Martínez, A López-Requena, S von Gunten, C Mesa; Havana (KU), Bern
- P37** **Mycophenolic acid successful therapy in a membranous glomerulonephritis due to Kimura disease**
JG Gaillard, SR Rotman, XG Girardet, FS Spertini; Lausanne, Sion
- P38** **Differential diagnosis between pancreatic ductal adenocarcinoma, chronic pancreatitis and autoimmune pancreatitis**
S Ghassem-Zadeh, H Acha-Orbea; Lausanne, Switzerland
- P39** **Fatigue in patients with Systemic Lupus Erythematosus – a cross-sectional study comparing the fatigue assessment scale (FAS) to the vitality dimension of the short-form SF-36 survey.**
A Horisberger, C Ribi; Lausanne

- P40** **Characterizing leucopenia in systemic lupus erythematosus – a cross-sectional study on peripheral blood mononuclear cells in 76 patients and 40 healthy controls**
A Horisberger, M Perreau, K Ohmiti, A Santos, C André, N Moreira Do Rosario, G Pantaleo, C Ribi
Swiss Systemic Lupus Erythematosus Cohort Study; Lausanne
- P41** **Safety and Tolerability of Human Immunoglobulin G, 20%, Administered Subcutaneously (IGSC 20%): Final Analysis of a Phase 2/3 Study in Patients with Primary Immunodeficiency Diseases in Europe**
M Borte, G Kriván, B Dérfalvi, L Maródi, F Dicső, W Engl, H Leibl, B McCoy, L Yel;
Leipzig (DE), Budapest (HU), Debrecen (HU), Nyíregyháza (HU), Vienna (AT), Cambridge (US)
- P42** **Safety of intravenous immunoglobulin 10% (KIOVIG) therapy in patients with autoimmune and Alzheimer's disease**
D Gelmont, RG Thomas, JA Dyck-Jones, S Fritsch, P Aisen, N Relkin, B McCoy, H Leibl, W Engl, V Empson, N Nikolov; Westlake Village (US), Vienna (AT), New York (US), Cambridge (US), Zürich
- P43*** **The role of S1PR1 agonism in thymus-dependent T-cell regeneration during acute graft-vs.-host disease**
M Vollmer, S Dertschnig, W Krenger; Basel, London (UK)
- P44** **Beta-trace protein interpretation algorithm for the diagnosis of cerebrospinal fluid leakage: a retrospective validation**
L Bernasconi, T Pötl, A Dellweg, F Metternich, AR Huber; Aarau
- P45** **Clinical features, diagnosis and treatment response of large-vessel vasculitis: retrospective cohort study from the University Hospitals of Genève**
M Posa, YD Muller, G Amzalag, JC Pache, JD Seebach; Genève
- P46*** **The Spleen – A Novel Niche for Chronic Myeloid Leukemia Stem Cells**
MA Amrein, ED Bühler, C Riether, AF Ochsenbein; Bern
- P47** **Comparison of five different methods to assess the presence of anti-DSF70 antibodies.**
AY Salimi, P Roux-Lombard; Genève
- P48*** **Adenovector minigene constructs and CD8+ T cell Memory Inflation**
JM Colston, B Bolinger, B Ludewig, P Klennerman; Oxford (UK), St.Gallen
- P49** **Next generation vaccine development against Alzheimer's disease**
F Zabel, M Maudrich, MF Bachmann; Zürich, Bern
- P50** **First human immunization with live-attenuated Mycobacterium tuberculosis: a randomized, double-blind, controlled phase I trial**
R Audran, R Chakour, O Karoui, V Steiner-Monard, A-Ch Thierry, CE Mayor, N Rettby, K Jatón, L Vallotton, C Lazor, J Doce, E Puentes, D Marinova, N Aguilo, C Martin and F Spertini;
Lausanne, Porriño (ES), Zaragoza (ES)
- P51** **A novel human skin model to study the role of inflammation in fibrosis development within scleroderma**
AM Dufour, M Alvarez, A Modarressi, P Quinodoz, NC Brembilla, C Chizzolini; Genève
- P52** **Generation and testing of a QB-amylin vaccine against Type 2 Diabetes Mellitus**
E Roesti, F Zabel, A El Turabi, M Vogel, M.F. Bachmann; Bern

- P53** **Potential of CCL22 to recruit mice T regulatory cells into rat islets xenografts**
D Muller, Montanari, Madelon, Meier, Gonelle-Gispert, Golshayan, H Buhler, D Seebach;
Genève, Lausanne

Clinical, laboratory and translational immunology – Group II

Posterdiscussion SSAI | Friday, April 29, 2016 | 11:30 – 12:30

- P54** **TNF blockade induces a dysregulated type I IFN response without autoimmunity in paradoxical psoriasis**
C Conrad, A Mylonas, J Di Domizio, C Belkhdja, O Demaria, AA Navarini, AK Lapointe, LA French, M Vernez, MF Gilliet; Lausanne, Zürich
- P55*** **IL-22-induced antimicrobial peptides are key determinants of mucosal vaccine-induced protection against H pylori in mice**
D Velin, M Moyat, H Bouzourene, W Ouyang, J Iovanna, JC Renault;
Lausanne, San Francisco (US), Marseille (FR), Brussels (BE)
- P56*** **The IL-33/ST2 pathway contributes to intestinal tumorigenesis in humans and mice**
KD Mertz, L Mager, MH Wasmer, T Junt, P Krebs; Liestal, Bern, Basel
- P57** **The oxysterol/EBI2 interaction and memory lymphocytes: attractive hosts in the world of multiple sclerosis**
AC Clottu, A Mathias, JD Seebach, R Du Pasquier, C Pot; Lausanne, Genève
- P58** **Homogenous responses of heterogeneous human melanoma cell lines to CD8 T cell attack**
NJ Neubert, SA Fuertes-Marraco, L Tillé, P Baumgaertner, C Soneson, D Barras, M Delorenzi, DE Speiser; Lausanne
- P59** **Neutrophil infiltration is associated with favorable prognosis in colorectal cancer: potential role of neutrophil/CD8+ T cell cross-talk.**
V Governa, V Mele, E Trella, R Drosier, L Quagliata, L Terracciano, N Kanna, G Iezzi, E Padovan, GC Spagnoli; Basel
- P60** **TN1K is important for the maintenance of chronic myeloid leukemia stem cells**
ED Bühner, MA Amrein, C Riether, AF Ochsenbein; Bern
- P61** **Assessing the Avidity Heterogeneity of mono- and polyclonal populations of Melanoma specific T cells.**
K Ioannidou, D Vanhecke, A Semilietof, C Grandclement, P Baumgaertner, P Gannon, M Allard, M Speiser, M Hebeisen, N Rufer, D Speiser; Lausanne, Zürich
- P62** **Discovery of new potential targets in dysfunctional CD8 T cells for cancer immunotherapy**
C Imbratta, M Giordano, AM Schmitt-Verhulst, DE Speiser, G Verdeil; Lausanne, Marseille (FR)
- P63** **Adhesion molecule JAM-C: a potential target for Mantle cell lymphoma therapeutics**
A Vijaya Kumar, C Donâte, B.A Imhof, T Matthes; Genève
- P64** **Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8 and CD4 T cell responses with multiple specificities including a novel DR7-restricted epitope**
P Baumgaertner, C Costa Nunes, A Cachot, H H. Maby-El Hajjami, L Cagnon, M Braun, L Derré, J-P Rivals, D Rimoldi, S Gnjatich, S Abed Maillard, P Marcos Mondéjar, E Romano, O Michielin, P Romero, D.E Speiser, C Jandus; Lausanne

- P65** **PD-L1 upregulation following RLR and TLR-based immunotherapy in a mouse model of gastric cancer.**
N Steinhoff, L Spagnuolo, I Mottas, T Spinetti, C Bourquin; Fribourg
- P66** **Identification of melanoma cells and lymphocyte subpopulations in metastatic lymph nodes by Fourier Transform Infrared imaging histopathology**
N Wald, N Bordry, P.G. Foukas, D. E. Speiser, E Goormaghtigh; Brussels (BE), Lausanne
- P67*** **A reversible mouse model of colitis allows to study the microbial, metabolic and immunological changes associated with remitting – relapsing inflammatory disorders in the intestine**
M Faderl, N Corazza, M Noti, J Brasseit, E Steiner-Althaus, CKC Kwong Chung, S Rihs, I Brodard, M Beutler, R Mars, V Perreten, M Geuking, K McCoy, A Macpherson, B Stecher, U Sauer, Ch Mueller; Bern, Munich (DE), Zürich
- P68** **Evidence for modulation of the innate and adaptive immune system in patients with primary antibody deficiency treated with IVIG**
S Viganò, F Indulsi, S Trabanelli, A Harari, P Romero, A Helbling, C Jandus, P Jandus; Lausanne, Bern, Genève
- P69** **CD56 bright NK cells in PBMC correlate with unfavorable clinical outcome in melanoma patients**
K de Jonge, P Baumgaertner, D Gfeller, DE Speiser; Lausanne

Allergology & Case Reports Allergology

Posterdiscussion SSAI | Friday, April 29, 2016 | 11:30 – 12:30

- P70** **Anaphylaxis due to pantoprazole – a rare event, a common drug**
V Virgini, A Künzler, P Schmid-Grendelmeier, M Glatz; Zürich, Baar, Davos
- P71*** **Anaphylaxis to gadolinium-based contrast media and cross-reactivity to other substances – 3 cases**
K Scherer, C Morales Mateluna, AJ Bircher; Basel
- P72*** **Cow's milk proteins in phytosanitary products: a new public health threat ?**
J Wassenberg, I Rochat, MA Panchard; Vevey, Lausanne
- P73** **Severe anaphylaxis to the antiseptic polyhexanide in a patient co-sensitized to chlorhexidine. Beware of hidden chlorhexidine sources.**
S Maître, F Spertini, C Ribí; Lausanne
- P74** **Innate immune system crosstalk: eosinophils mediate immune modulation of dendritic cells through exosomes as shuttle vectors**
F Cortinas-Elizondo, K Frias Boligan, D Simon, HU Simon, S von Gunten; Bern
- P75** **A knockin mouse model using CRISPR-CAS9 system to study SHM and CS of germline anti-Fel d 1 antibodies**
LS Zha, M Vogel, MF Bachmann, P Pelczar; Bern, Basel

First Announcement



Frühjahrsversammlung 2017

Assemblée de printemps 2017

15.-16. Juni 2017

15-16 juin 2017

Forum Messe, Luzern
www.orl-hno.ch

Posters SSORL

(candidates Best of Papers SSORL are marked with #)

- P76** **A migrating bullet in the parapharyngeal space? A case report and ballistic reconstruction**
 *Bächinger D, Bolliger S, Huber GF, Laske RD; Zürich
- P77** **Acute inflammatory edema of both eyelids – a difficult differential diagnosis.**
 Iliadou E, Ziglinas P, Lang FJW; Fribourg
- P78** **Akute Fazialisparese nach Mittelohroperation: Was? Wann? Wie? Wo?**
 *Steger L, Fischer C; Chur
- P79** **An unusual case of persisting bilateral swelling of the parotid gland**
 Pucci M, Jerónimo A, Konu P, Lang FJW; Fribourg
- P80** **Bifid uvula in Genève's school children: a cross sectional study**
 *Feka P, Banon J, Leuchter I, La Scala G; Genève
- P81** **Céphalée en grappe : Un nouvel espoir thérapeutique par stimulation du ganglion sphénoalatin.**
 *Holtz F, Lamercy K, Ikonomidis C, Peciu-Florianu I, Bloch J, Pasche P; Lausanne
- P82** **Chylothorax after thyroidectomy: a case report and systematic review**
 *Pichler J, Merki V, Giger R, Mantokoudis G; Bern
- P83** **Co-targeting the MET and PI3K pathways in head and neck cancer: Impact of PIK3CA hotspot mutations E545K and H1047R**
 *Nisa L, Giger R, Häfliger P, Poliaková M, Aebersold DM, Charles RP, Caversaccio MD, Medová M, Zimmer Y; Bern
- P84** **Correlation between podoplanin expression and extracapsular spread in squamous cell carcinoma of the oral cavity and the oropharynx**
 *Mermod M, Bongiovanni M, Petrova TV, Dubikovskaya EA, Simon C, Tolstonog G, Monnier Y; Lausanne
- P85** **Development and Validation of the Zürich Chronic Middle Ear Inventory (ZCMEI-21): An Electronic Questionnaire for Assessing Quality of Life in Patients with Chronic Otitis Media**
 *Bächinger D, Rösli C, Ditzel B, Huber AM; Zürich, Heidelberg (DE)
- P86** **Does Functional Expansion Pharyngoplasty improve Surgical Results in Adults with Sleep-related Breathing Disorders?**
 Brumann M, Zehnder J, Horvath L, Tschopp K; Liestal
- P87** **Does Hearing Preservation after Cochlear Implantation Influence Speech Perception under Electric-Only Condition?**
 *Dalbert A, Pfiffner F, Baumann N, Veraguth D, Rösli C, Huber A; Zürich
- P88** **Ein 19 jähriger Patient mit Schluckbeschwerden**
 *Fellmann J, Laske R, Steiner U, Kleijung T; Zürich
- P89** **Endoscopic Middle Ear Anatomy: Variants of Hypo- and Retrotympanon**
 *Ansuetz L, Bonali M, Presutti L, Caversaccio M; Bern, Modena (IT)
- P90** **Evaluation of Long Term Effect of Intratympanic Dexamethason Therapy (ITD) in Menière's Disease (MD)**
 *Blätter M, Candrea C, Lehner A, Gärtner M, Linder T; Luzern

Posters SSORL

(candidates Best of Papers SSORL are marked with #)


- P91** **Fremdspracherwerb bei Kindern mit angeborener Gehörlosigkeit und Cochleaimplantat(en)**
*Beeres RJ, Candrea C, Ohnsorg C, Castellanos S, DeMin N, Linder T; Luzern
- P92** **From Butterfly to Eagle**
*Kamp FA, Muller L, Bodmer D; Basel
- P93** **Hypothyreose nach Hemithyroidektomie**
Elmas F, Lauber F, Müller W; Luzern, Zürich
- P94** **Interdisciplinary therapy in patients planned for dental implant surgery with radiographic abnormalities in the maxillary sinus: The Bernese concept**
*Buser N, Bornstein M, Buser D, Caversaccio MD; Bern
- P95** **Intra-Cochlear Hemorrhage Imaging in Sensorineural Hearing Loss**
*Morrison M, Alianou A, Becker M, Senn P; Genève
- P96** **Intraoperative, mobile, digitale Volumetomographie im HNO-Bereich: Erste Erfahrungen**
*Waser M, Mantokoudis G, Gerber N, Gerber K, Williamson T, Weber S, Wagner F, Vischer M, Caversaccio M; Bern
- P97** **La sténose sousglottique comme première manifestation de maladie inflammatoire systémique.**
De Maesschalck T, Leuchter I, Seebach J; Genève
- P98** **La tularémie : imitatrice d'un carcinome épidermoïde de l'oropharynx**
*Vinckenbosch P, Reinhard A, Monnier Y, Lambercy K, Bisig B, Simon C; Lausanne
- P99** **Listening to Music after SSD Cochlear Implantation**
Brockmeier SJ, Mlynski R, Radeloff A, Stark T, Teschke C; Aarau, Würzburg (DE), München (DE)
- P100** **Multimodale Behandlung eines Tumors des Sinus maxillaris aus dem Formenkreis der Ewing Sarkome**
*Fürer R, Prestin S; Aarau
- P101** **Myxome de l'espace parapharyngé : un case-report**
Lambiel S, Leuba D, Lardon N, Gremaud M, Jaquet Y; Neuchâtel
- P102** **Ohrmuschelkorrektur mit dem Ear Well System**
Candrea C, Pabst G, Linder TE; Luzern
- P103** **Olfactory function after midface fractures**
*Serex CA, Terzic A, Friedrich H, Landis BN; Genève, Bern
- P104** **Olfactory function in healthy subjects is not influenced by caffeine**
*Hasler CAI, Hummel T, Welge-Lüssen A; Olten, Basel, Dresden
- P105** **Olfaktorisches Neuroblastom. Ist eine Radiotherapie immer erforderlich?**
*Schmid P, Nikolaou G, Rössle M, Soyka M, Holzmann D; Zürich, Chur
- P106** **Permanent Postoperative Anosmia – a systematic review**
*Alotaibi N, Landis BN; Genève
- P107** **Progressive hypoacusis with pulsatile tinnitus and pulsatile mass after parotidectomy.**
Pucci M, Asanau A, Lang FJW; Lausanne

Posters SSORL

(candidates Best of Papers SSORL are marked with #)

- P108** **Sarkomatoides Karzinom des Larynx, eine seltene Entität.**
Schwarzkopf M, Muller L; Basel
- P109** **SMAS flap in the prevention of Frey syndrome: a meta-analysis**
Dulguerov N, Makni A, Dulguerov P; Genève
- P110** **Stereotaktische Cochleostomie in einem experimentellen Set-Up**
*Péus D, Dobrev I, Prochazka L, Pfiffner F, Sürücü O, Boss A, Rösli C, Sim JH, Huber AM; Zürich
- P111** **Taugt das Schaf als Modell für das menschliche Mittel- und Innenohr?**
*Péus D, Pfiffner F, Dobrev I, Prochazka L, Thoele K, Dalbert A, Boss A, Rösli C, Sim JH, Huber AM; Zürich
- P112** **Teratom mit „somatic-type malignancy“ in Form eines hochdifferenzierten, teils sklerosierten Liposarkoms des Pharynx**
*Listyo A, Baumhoer D, Storck C; Basel

First Announcement



INSELSPITAL
UNIVERSITÄTSSPITAL BERN
BERN UNIVERSITY HOSPITAL

Patronage



Schweizerische Gesellschaft für Oto-Rhino-Laryngologie, Hals- und Gesichtschirurgie
Société suisse d'Oto-Rhino-Laryngologie et de Chirurgie cervico-faciale
Società Svizzera di Otorinolaringoiatria e di Chirurgia cervico-facciale
www.orl-hno.ch

13th Congress of the European Federation of Audiology Societies

June 7 – 10, 2017

Congress Centre Kursaal Interlaken | Switzerland
www.efas2017.org

Invited Speakers & Chairs Joint SSORL/SSAI Meeting 2016

Page

A

- 33 **Prof. Hans Acha-Orbea, PhD**
UNIL
Department of Biochemistry
Chemin des Boveresses 155
1066 Epalinges, CH
- 33 **Prof. Ruedi Aebersold, PhD**
ETH Zürich
Institut für Molekulare Systembiologie
Auguste-Piccard-Hof 1
8093 Zürich, CH
- 37 **Lionel Arlettaz, MD, PhD**
Institute Central des Hôpitaux
Service d'Immunologie et d'Allergologie
Av. Grand-Champsec 86
1950 Sion, CH

B

- 23 **Prof. Martin Bachmann, PhD**
Inselspital Bern
Universitätsklinik für Rheumatologie, Immunologie
und Allergologie
Salihaus 2
3010 Bern, CH
- 23 **Prof. Christoph Berger, MD**
Kinderspital Zürich - Eleonorenstiftung
Infektiologie & Spitalhygiene
Steinwiesstrasse 75
8032 Zürich, CH
- 25 **Prof. Andreas Bircher, MD**
Universitätsspital Basel
Allergology
Petersgraben 4
4031 Basel, CH
- 33 **PD Pierre-Yves Bochud, MD**
CHUV
Service des Maladies Infectieuses
Rue du Bugnon 46
1011 Lausanne, CH
- 32 **Prof. Daniel Bodmer, MD**
Universitätsspital Basel
Hals-Nasen-Ohren-Klinik
Petersgraben 4
4031 Basel, CH

Page

- 32 **Prof. Carole Bourquin, MD, PhD**
University of Fribourg
Department of Medicine
Ch. du Musée 8
1700 Fribourg, CH

- 38 **Prof. Onur Boyman, MD**
UniversitätsSpital Zürich
Klinik für Immunologie
Gloriastrasse 23
8091 Zürich, CH

- 38 **Katrin Brunner**
aha! Allergiezentrum Schweiz
Scheibenstrasse 20
3014 Bern

C

- 33 **Prof. Carlo Chizzolini, MD**
HUG
Service d'Immunologie et Allergologie
Rue Micheli-du-Crest 24
1211 Genève, CH
- 21 **Bernard Clot, PhD**
Biometeorologie
Messungen und Daten
MeteoSchiweiz
Ch. de l'Aérolologie 1
1530 Payerne, CH
- 39 **Noam A. Cohen, MD, PhD**
University of Pennsylvania
UPHS, Department of ORL/HNS
3400 Spruce Street, Ravdin Building 5th Fl.
Philadelphia, PA 19104-4283, US
- 33 **Prof. George Coukos, MD, PhD**
Ludwig Center for Cancer Research
of the University of Lausanne
Département d'oncologie UNIL-CHUV
Rue du Bugnon 46
1011 Lausanne, CH

D

- 38 **PD Eric Dayer, MD**
Institut Central des Hôpitaux
Service Immunologie et Allergologie
Av. Grand-Champsec 86
1950 Sion, CH

Invited Speakers & Chairs Joint SSORL/SSAI Meeting 2016

Page

- 29 **Anne-Emmanuelle de Crousaz**
Euresearch Lausanne UNIL-EPFL
c/o EPFL
Station 5 - Bureau PPH 351
1015 Lausanne, CH
- 19 **Prof. Gennaro De Libero, MD**
University of Basel
Department of Biomedicine
University Hospital
Hebelstrasse 30
4031 Basel, CH
- 27 **Prof. Michele De Palma, PhD**
EPFL
School of Life Sciences
ISREC-Swiss Institute for
Experimental Cancer Research
UPDEPALMA
SV 2527, Station 19
1015 Lausanne, CH
- F**
- 38 **Petra Felder**
Product Manager eHealth (vivates)
Post CH AG
Entwicklung und Innovation
Wankdorfallee 4
3030 Bern, CH
- 33 **Giovanni Ferrari, MD**
Ospedale Regionale di Bellinzona e Valli
Allergy Unit
Dermatology Department
Via Ospedale
6500 Bellinzona, CH
- 35 **Prof. Daniela Finke, MD**
Universitäts Kinderspital beider Basel
Developmental Immunology
Mattenstrasse 2
84058 Basel, CH
- 19 **Lukas Flatz, MD**
Kantonsspital St.Gallen
Institute of Immunobiology
Rorschacherstrasse 95
9007 St.Gallen, CH

G

- 33 **Prof. Thomas F. Gajewski, MD, PhD**
The University of Chicago Medicine
5841 S. Maryland Avenue, MC 2115
Chicago, IL 60637, US

Page

- 18 **Prof. Philippe Gevaert, MD**
Ghent University
Faculty of Medicine and Health sciences
Department of Otorhinolaryngology
De Pintelaan 185 1P1
9000 Gent, BE
- 27 **Elisa Gomez Perdiguero, PhD**
Macrophages and endothelial cells
Department of Developmental and
Stem Cell Biology
Institut Pasteur/CNRS URA2578
Bâtiment Jacques Monod
25 rue du Docteur Roux
75015 Paris, FR
- 18 **Santiago Gonzalez, PhD, PhD**
Università della Svizzera Italiana
Institute for Research in Biomedicine
Infection and Immunity
Via Vincenzo Vela 6
6500 Bellinzona, CH
- 29 **Prof. Greta Guarda, PhD**
UNIL
Department of Biochemistry
Chemin des Boveresses 155
1066 Epalinges, CH
- 21 **Pierre Gumowski, MD**
INRAAIC
Institut de Recherche Appliquée en
Allergologie et Immunologie Clinique
302 route de Meyrin
1217 Meyrin-Genève, CH
- H**
- 33 **Prof. John Haanen, PhD**
Netherlands Cancer Institute
Division Immunology
Plesmanlaan 121
1066CX Amsterdam, NL
- 16 **Dominik Harder, MD**
Brunnenhof Praxis
Gäuggelistrasse 20
7000 Chur, CH
- 32 **Thomas Hauser, MD**
Immunologie-Zentrum
Walchestrass 11
8006 Zürich, CH Zürich

Invited Speakers & Chairs Joint SSORL/SSAI Meeting 2016

Page

- 37 **Ingmar Heijnen, MD, PhD**
Universitätsspital Basel
Medizinische Immunologie
Petersgraben 4
4031 Basel, CH
- 37 **Prof. Werner Held, PhD**
UNIL
Department of Oncology
Ch. des Boveresses 15
51066 Epalinges, CH
- 16 **Alice Horisberger, MD**
CHUV
Service d'immunologie et allergie
Rue du Bugnon 21
1011 Lausanne, CH
- 33 **PD Wolfram Hötzenecker, MD**
UniversitätsSpital Zürich
Dermatologische Klinik
Rämistrasse 100
8091 Zürich, CH
- I**
- 27 **Prof. Beat Imhof, PhD**
Université de Genève
Faculté de médecine
Département de pathologie et immunologie
Rue Michel-Servet 1
1211 Genève, CH
- K**
- 25 **Atsushi Kato, PhD**
Northwestern University
Feinberg School of Medicine
Division of Allergy-Immunology
240 E Huron
Chicago IL 60611, US
- 39 **Prof. Stefan H. E. Kaufmann, PhD**
Max-Planck-Institut für Infektionsbiologie
Abteilung für Immunologie
Charitéplatz 1
10117 Berlin, DE
- 27 **Prof. Manfred Kopf, PhD**
ETH Zurich
Institute for Molecular Health Sciences
Otto-Stern-Weg 7
8053 Zürich, CH

Page

- 35 **Ruth Köppl, MD**
Universitätsspital Basel
HNO-Klinik
Petersgraben 4
4031 Basel, CH
- 19 **Carsten Krieg, PhD**
URPP Translational Cancer Research
Universität Zürich
Institut für Experimentelle Immunologie
Winterthurerstrasse 190
8057 Zürich, CH
- L**
- 16 **PD Basile Landis, MD**
HUG
ORL/Chirurgie Cervico-Faciale
Rue Gabrielle Perret-Gentil 4
1205 Genève, CH
- 18 **Sylvain Latour, MD**
Institut IMAGINE
Institut des maladies génétiques
24, Boulevard de Montparnasse
75015 Paris, FR
- 16 **Annette Leimgruber, MD**
Rochettaz 2
1009 Pully, CH
- 25 **Prof. Georg Lenz, MD**
Universitätsklinikum Münster
Leiter Translationale Onkologie
Medizinische Klinik A
Albert-Schweitzer-Campus 1
48149 Münster, DE
- 23 **Prof. Burkhard Ludewig, MD**
Kantonsspital St.Gallen
Laborforschungsabteilung
Rorschacherstrasse 95
9007 St.Gallen, CH
- 35 **Prof. Sanjiv Luther, PhD**
UNIL
Department of Biochemistry
Chemin des Boveresses 155
1066 Epalinges, CH

Invited Speakers & Chairs Joint SSORL/SSAI Meeting 2016

Page

M

- 25 **Thomas Marichal, DVM, PhD**
University of Liège
GIGA-Research B34
Cellular and Molecular Immunology
Avenue de l'Hôpital 1
4000 Liège, BE
- 25 **Prof. Benjamin Marsland, MD**
CHUV
Service de pneumologie
Chemin des Boveresses 155
1066 Epalinges, CH
- 38 **Claude Olivier Marti, PhD**
Promed SA
Laboratoire medical
Microbiologie
Ancienne Papeterie 131
1723 Marly, CH
- 33 **Prof. Fabio Martinon, PhD**
UNIL
Department of Biochemistry
Chemin des Boveresses 155
1066 Epalinges, CH
- 21 **Prof. Olivier Michel, MD**
Université Libre de Bruxelles
CHU Brugmann
Clinique d'Immuno-allergologie
Laboratoire de médecine expérimentale
Place Van Gehuchten 4
1020 Bruxelles, BE
- 37 **Silvia Monticelli, PhD**
Università della Svizzera Italiana
Institute for Research in Biomedicine
via Vincenzo Vela 6
6500 Bellinzona, CH
- 25 **Prof. Dr. Anne Müller**
University of Zurich
Institute of Molecular Cancer Research
Winterthurerstrasse 190
8057 Zürich, CH
- 17 **Prof. Christoph Müller, PhD**
Universität Bern
Pathologie
Murtenstrasse 31
3010 Bern, CH

58

Page

N

- 17 **Natalie Neubert, PhD candidate**
UNIL
Ludwig Center for Cancer Research
Département d'oncologie fondamentale
Route de la Corniche 9A
1066 Epalinges, CH
- 27 **Prof. Sussan Nourshargh, PhD, FMedSci**
Centre for Microvascular Research
William Harvey Research Institute
Barts and The London School of
Medicine and Dentistry
Queen Mary, University of London
Charterhouse Square
London, EC1M 6BQ, UK

O

- 21 **Måns Österberg, PhD**
Allergon AB
Välingeavägen 309
262 92 Ängelholm, SE
- 29 **Prof. Annette Oxenius, PhD**
ETH Zürich
Institut für Mikrobiologie
Vladimir-Prelog-Weg 4
8093 Zürich, CH

P

- 39 **Prof. Ed Palmer, MD**
Universitätsspital Basel
Department Biomedizin
Hebelstrasse 20
4031 Basel, CH
- 27 **Prof. Philippe Pasche, MD**
CHUV
Département ORL
Rue du Bugnon 46
1011 Lausanne, CH
- 25 **Prof. Ian Pavord, DM FRCP**
University of Oxford
NDM Research Building
Nuffield Department of Medicine
Old Road Campus
Roosevelt Drive
Oxford, OX3 7FZ, UK
- 39 **Prof. Daniel Pinschewer, MD**
University of Basel
Department of Biomedicine
Experimental Virology
Petersplatz 10
4009 Basel, CH

Invited Speakers & Chairs Joint SSORL/SSAI Meeting 2016

Page

- 29 **Bernd Pulverer, PhD**
EMBO Scientific Publications
Postfach 1022.40,
69012 Heidelberg, DE
- R**
- 18 **Prof. Janine Reichenbach, MD**
Kinderspital Zürich – Eleonorenstiftung
Pädiatrische Immunologie
Steinwiesstrasse 75
8032 Zürich, CH
- 33 **Prof. Walter Reith, MD**
University of Geneva
Département de pathologie et immunologie
Rue Michel-Servet 1
1211 Genève, CH
- 16 **Camillo Ribi, MD**
CHUV
Service d'immunologie et allergie
Rue du Bugnon 46
1011 Lausanne, CH
- 33 **PD Thierry Roger, PhD**
CHUV
Service des maladies infectieuses
Chemin des Boveresses 155
1066 Epalinges, CH
- 18 **Prof. Pedro Romero, MD**
UNIL
Ludwig Center for Cancer Research
Département d'oncologie UNIL-CHUV
Rue du Bugnon 46
1011 Lausanne, CH
- 18 **Prof. Pascale Roux-Lombard, MD**
HUG
Service d'immunologie et d'allergologie
Rue Gabrielle Perret-Gentil 4
1211 Genève, CH
- S**
- 38 **Salima Sadallah, MD**
Universität Basel
Departement Biomedizin
Hebelstrasse 20
4031 Basel, CH
- 39 **Federica Sallusto, PhD**
Università della Svizzera Italiana
Institute for Research in Biomedicine
via Vincenzo Vela 6
6501 Bellinzona, CH

Page

- 32 **Prof. Alain Saraux, MD**
CHU de la Cavale-Blanche
Service de Rhumatologie
Boulevard Tanguy Prigent
29609 Brest Cedex, FR
- 21 **PD Kathrin Scherer Hofmeier, MD**
Universitätsspital Basel
Dermatologie
Petersgraben 4
4031 Basel, CH
- 39 **Chris Schiering, PhD**
The Francis Crick Institute
Mill Hill Laboratory
The Ridgeway
NW7 1AA London, UK
- 38 **Adrian Schmid**
"eHealth Suisse"
Koordinationsorgan Bund-Kantone
Schwarzenburgstrasse 157
3003 Bern
- 21 **Prof. Peter Schmid-Grendelmeier, MD**
UniversitätsSpital Zürich
Allergiestation
8091 Zürich, CH
- 27 **Thomas Schweri, MD**
Hans-Hugi-Strasse 10
2502 Biel/Bienne, CH
- 18 **Prof. Jörg Seebach, MD**
HUG
Service d'immunologie et d'allergologie
Rue Gabrielle Perret-Gentil 4
1211 Genève, CH
- 33 **Prof. Christian Simon, MD**
35 CHUV
Service d'oto-rhino-laryngologie et
de chirurgie cervico-faciale
Rue du Bugnon 46
1011 Lausanne, CH
- 16 **PD Michael Soyka, MD**
18 UniversitätsSpital Zürich
32 Klinik für Ohren-, Nasen-, Hals- und
Gesichtschirurgie
Frauenklinikstrasse 24
8091 Zürich, CH

Preannouncement



ssp sgp

SWISS SOCIETY OF PAEDIATRICS

Ihre Ärztinnen und Ärzte für Kinder und Jugendliche

Les médecins de vos enfants et adolescents

I medici dei vostri bambini e adolescenti



Swiss Society
for Allergology
and Immunology

Joint SSP/SSAI Annual Congress 2017

Swiss Society of Pediatrics
Swiss Society of Allergology and Immunology

«Crossroads of Interdisciplinary Medicine»

June 1–2, 2017

OLMA Messen, St. Gallen

<http://bbscongress.ch/2017/sgp-ssai-2017/>

Jointly organized with the
4th Lymphoid Tissue Meeting
«Focus on: Stromal Cells»
June 3, 2017

Speakers & Chairs Joint SSORL/SSAI Meeting 2016

Page		Page	
			V
39	Prof. Jens Stein, PhD Universität Bern Theodor Kocher Institut Freiestrasse 1 3011 Bern, CH	23	Prof. Sjoerd H. van der Burg, PhD Leiden University Medical Center Department of Clinical Oncology Albinusdreef 2 2333 Leiden, NL
33	Prof. Giulio Superti-Furga, PhD Research Center for Molecular Medicine of the Austrian Academy of Sciences Lazarettgasse 14 1090 Vienna, AT	18	KD Dorothe Veraguth, MD UniversitätsSpital Zürich Klinik für Ohren-, Nasen-, Hals- und Gesichtschirurgie Frauenklinikstrasse 24 8091 Zürich, CH
32	Prof. Sandro Stöckli, MD Kantonsspital St.Gallen Hals-Nasen-Ohrenklinik Rorschacherstrasse 95 9007 St.Gallen, CH	33	Prof. Stephan von Gunten, MD, PhD, MME Universität Bern Institut für Pharmakologie Inselspital - INO-F 3010 Bern, CH
	T		W
19	Marcus Thelen, PhD Università della Svizzera Italiana Institute for Research in Biomedicine Via Vincenzo Vela 6 6500 Bellinzona, CH	18	Prof. Klaus Warnatz, MD Medical Center - University of Freiburg Center for Chronic Immunodeficiency at Center for Translational Cell Research Breisacher Strasse 117 79106 Freiburg, DE
25	Prof. Margot Thome, PhD UNIL Department of Biochemistry Chemin des Boveresses 155 1066 Epalinges, CH	16	Prof. Antje Welge-Lüssen, MD
32	Prof. Isabelle Touitou, MD, PhD Centre Hospitalier Régional Universitaire de Montpellier Génétique des maladies rares et auto-inflammatoires 371, avenue du doyen Gaston Giraud 34295 Montpellier cedex, FR	39	Universitätsspital Basel Hals-Nasen-Ohren-Klinik Petersgraben 4 4031 Basel, CH
38	Prof. Marten Trendelenburg, MD Universitätsspital Basel Abteilung für Innere Medizin Petersgraben 4 4031 Basel, CH	25	Sandra Wieser (Pahr), PhD MedUni Wien Institut für Pathophysiologie und Allergieforschung Spitalgasse 23 1090 Wien, AT
17	Riccardo Turrini, PhD UNIL Département d'oncologie fondamentale Route de la Corniche 9A 1066 Epalinges, CH		Z
		39	Prof. Dietmar Zehn, MD, PhD Technical University Munich School of Life Sciences Weihenstephan Division of Physiology and Immunology 80333 Munich, DE

Opening hours of the industrial exhibition

Thursday, April 28th, 2016: 08:15-18:30 h

Friday, April 29th, 2016: 07:30-17:00 h


List of exhibitions

Alphabetical order

Nr.	Company
29	A. Menarini
9	Aerobiological Village
11	aha! Allergiezentrum Schweiz
8	ALK-Abello AG
52	Allergopharma
38a	Amplifon AG
49	Anklin
38b	ATMOS Medical AG
28	Atos Medical
18	AUDIOCARE AG
45	Baxalta Schweiz AG
30	Becton Dickinson AG
54	Bien-Air Surgery SA
34	BioConcept
42	Biotest (Schweiz) AG
51	Carl Zeiss AG
31	Cochlear AG
41	CSL Behring AG
1	Diatec AG
22	Eisenhut Instrumente GmbH
57	endodoctor (Schweiz) GmbH
23	EST! Medizintechnik AG
21	EUROIMMUN Schweiz AG
32	Haag-Streit AG
5	Halmed / Fiagon
2	Innoforce Est.
48	Interdelta SA
43	KB Medizin Technik GmbH
40	Marcel Blanc & Otopront
50	MEDA Pharma GmbH
17	Mediconsult AG
6	Meditrend SA
20	Medtronic (Schweiz) AG
37	Neuroth Hörcenter AG
39	Novartis Pharma Schweiz AG
53	Novimed AG
24	OSCIMED SA
15	OTICON SA
4	Piota Medical SA
33	ResMed Schweiz AG
44	RUWAG Handels AG
58	Schwabe Pharma AG
35	SHIRE Switzerland GmbH
3	Siemens & Co
14	Stallergenes AG
56	STEMCELL Technologies
16	Teomed AG
36	Thermo Fisher Scientific
47	Vifor SA
12+13	XION GmbH
19	Zambon Svizzera SA
46	Zeller Medical


By booth number

Nr.	Company
1	Diatec AG
2	Innoforce Est.
3	Siemens & Co
4	Piota Medical SA
5	Halmed / Fiagon
6	Meditrend SA
8	ALK-Abello AG
9	Aerobiological Village
11	aha! Allergiezentrum Schweiz
12+13	XION GmbH
14	Stallergenes AG
15	OTICON SA
16	Teomed AG
17	Mediconsult AG
18	AUDIOCARE AG
19	Zambon Svizzera SA
20	Medtronic (Schweiz) AG
21	EUROIMMUN Schweiz AG
22	Eisenhut Instrumente GmbH
23	EST! Medizintechnik AG
24	OSCIMED SA
28	Atos Medical
29	A. Menarini
30	Becton Dickinson AG
31	Cochlear AG
32	Haag-Streit AG
33	ResMed Schweiz AG
34	BioConcept
35	SHIRE Switzerland GmbH
36	Thermo Fisher Scientific
37	Neuroth Hörcenter AG
38a	Amplifon AG
38b	ATMOS Medical AG
39	Novartis Pharma Schweiz AG
40	Marcel Blanc & Otopront
41	CSL Behring AG
42	Biotest (Schweiz) AG
43	KB Medizin Technik GmbH
44	RUWAG Handels AG
45	Baxalta Schweiz AG
46	Zeller Medical
47	Vifor SA
48	Interdelta SA
49	Anklin
50	MEDA Pharma GmbH
51	Carl Zeiss AG
52	Allergopharma
53	Novimed AG
54	Bien-Air Surgery SA
56	STEMCELL Technologies
57	endodoctor (Schweiz) GmbH
58	Schwabe Pharma AG




Hall overview

Ground floor



Hall overview

Basement



*Ihr verlässlicher
Partner für Bera-
tung & Service.*

*Votre partenaire
de confiance pour
le conseil et les
services.*

**Damit Sie sich auf Ihre Patienten
konzentrieren können.**

*Afin que vous puissiez vous concentrer
exclusivement sur vos patients.*



Ersatzteile
Pièces de rechange



Diagnostik
Diagnostic



Behandlung
Traitement



Beratung
Conseils

**Ihre Bedürfnisse.
Unser Service.
Vos besoins.
Notre service.**



Audiologie
Audiologie



Chirurgie
Chirurgie



Hygiene
Hygiène



EDV
Informatique

Das **andere** Antihistaminikum^{1,2}

L'antihistaminique **différent**^{1,2}



BILAXTEN®
bilastinum 20 mg

¹ Scaglione, F. et al.; Safety profile of Bilastine: 2nd generation H1-antihistamines. Eur. Med. Pharmacol. Sc. 2012; 16:1999-2005. | ² Kuna P. et al.; Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy 2009; 39 (9): 1338-1347.



BILAXTEN® Z: Tbl zu 20 mg Bilastin. **I:** Symptomatische Behandlung der saisonalen allergischen Rhino-Konjunktivitis und Urtikaria. **D:** Erwachsene und Jugendliche über 12 Jahre: 1 Tbl 1 x täglich 1 Stunde vor oder 2 Stunden nach der Einnahme von Nahrung oder Fruchtsaft. **KI:** Überempfindlichkeit auf Wirkstoff oder andere Bestandteile der Tabletten. **VM:** Co-Medikation mit P-Glycoprotein-Inhibitoren, Patienten mit mässiger Niereninsuffizienz. Keine ausreichende Erfahrung bei schwerer Nieren- oder Leberinsuffizienz. **IA:** Nahrung, Grapefruitsaft, Keto-konazol oder Erythromycin, Diltiazem. **UAW:** Häufig: Kopfschmerzen, Schwindel, Müdigkeit. Gelegentlich: gesteigerter Appetit, Angstgefühl, Schlaflosigkeit, GI-Beschwerden. **P:** 10°, 30°, 50°, (B) *kassenzulässig Ausführliche Informationen finden Sie unter www.swissmedinfo.ch. A. Menarini AG, 8052 Zürich. V.01 P-2899_D_03/16